2 Characteristics of included studies

Study Name	Year	No. of arms included in NMA	No of total study arms	Drug	Sponsored	No. randomised	Mean age (SD)	% Female	Dose (min-max, mg daily)	Dosing Schedule	Mean Dose Delivered	Baseline Severity Scale	Mean Baseline Severity	Length of trial (weeks)	Diagnostic Criteria	Recruitment	Multi/ Single Centre	Treatment Setting	Patient Status	Placebo Run in	Rescue Medication
Aberg-Wisted 2000	2000	2	2	paroxetine	No	177	*	*	20-40	Flexible	*	MADRS	30.70	8	DSM-III-R	Europe	Multi-center	Unclear	Outpatients only	No	Unclear
				sertraline	No	176	*	*	50-150	Flexible	*	MADRS	30.30								
Aguglia 1993	1993	2	2	sertraline	No	52	57.5 (15.5)	*	50-150	Flexible	72	HAMD 17	24.80	8	DSM-III-R	Europe	Multi-center	Unclear	Outpatients only	Yes	Unclear
				fluoxetine	No	56	58.9 (17.3)	*	20-60	Flexible	28	HAMD 17	25.10								
AK1102365	unpublished	2	2	bupropion	Yes	166	36.8 (9.3)	0.47	200-300	Flexible	*	HAMD 17	19.40	12	*	Asia	Multi-center	Unclear	Unclear	No	Unclear
				placebo	No	159	36 (8.9)	0.44	0-0	Flexible	0	HAMD 17	19.80								
Alexopoulos 2004 (poster SCT-MD-27)	2004	3	3	escitalopram	Yes	136	39.5 (10.7)	*	10-20	Flexible	*	HAMD 24	26.47	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				sertraline	No	138	40 (11.4)	*	50-200	Flexible	*	HAMD 24	26.15								
				placebo	No	135	40.6 (12.3)	*	0-0	Flexible	0	HAMD 24	27.29								
Allard 2004	2004	2	2	citalopram	No	75	72.5 (5.7)	*	20-30	Flexible	26	MADRS	27.00	8	DSM-IV	Europe	Multi-center	Unclear	Outpatients only	No	Unclear
				venlafaxine	Yes	76	73.6 (5.9)	*	75-150	Flexible	116	MADRS	27.60								
Altamura 1989b	1989	2	3	amitriptyline	Unclear	37	66.43 (5.6)	0.57	75-75	Fixed	75	HAMD 21	29.03	5	DSM-III	Europe	Multi-center	Unclear	Inpatients only	Unclear	Unclear
				trazodone	Unclear	36	64.61 (5.7)	0.61	150-150	Fixed	150	HAMD 21	29.68								
Alvarez 2012 (11492A, NCT00839423)	2012	4	4	placebo	No	105	42 (10.9)	0.66	0-0	Fixed	0	HAMD 24	29.70	6	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				vortioxetine	Yes	109	43.8 (11.6)	0.64	5-5	Fixed	5	HAMD 24	29.90								
				vortioxetine	Yes	101	42.3 (13.1)	0.65	10-10	Fixed	10	HAMD 24	29.30								
				venlafaxine	No	114	45 (10.3)	0.54	225-225	Fixed	225	HAMD24	29.40								
Alves 1999	1999	2	2	fluoxetine	No	47	42.3 (12.2)	*	20-40	Flexible	*	HAMD 21	26.90	12	DSM-IV	Europe	Multi-center	Unclear	Outpatients only	No	Unclear
				venlafaxine	Yes	40	45.4 (12)	*	75-150	Flexible	*	HAMD 21	27.90								
Amin 1984	1984	2	3	fluvoxamine	Yes	161	42 (*)	*	*	Flexible	155	HAMD unspecified	22.60	4	Feighner	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	Unclear	Unclear
				placebo	No	150	42 (*)	*	0-0	Flexible	0	HAMD unspecified	22.70								

Amini 2005	2005	2	2	mirtazapine	No	18	35 (10.6)	*	30-30	Fixed	30	HAMD 17	25.80	6	DSM-IV	Asia	Single center	Secondary /Tertiary care	Both	No	Unclear
				fluoxetine	No	18	37.7 (11.3)	*	20-20	Fixed	20	HAMD 17	24.80								
Amsterdam 1986	1986	2	3	amitriptyline	No	55	41 (12)	*	200-300	Flexible	182	HAMD 21	24.5	4	RDC	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	54	41 (12)	*	0-0	Flexible	0	HAMD 21	23.4								
Andersen 1986	1986	2	2	citalopram	Unclear	57	*	0.70	40-40	Fixed	40	HAMD 17	22.5	5	*	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				clomipramine	Unclear	57	*	0.69	150-150	Fixed	150	HAMD17	22								
Ansseau 1989a	1989	3	3	milnacipran	Unclear	47	48.6 (10.9)	0.66	50-50	Fixed	50	HAMD 17	25.10	4	RDC	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				milnacipran	Unclear	48	48.6 (10.9)	0.66	100-100	Fixed	100	HAMD 17	24.40								
				amitriptyline	No	49	48.6(10.9)	0.66	150-150	Fixed	150	HAMD 17	24.80								
Ansseau 1989b	1989	2	2	milnacipran	Unclear	44	49.6 (11.6)	*	200-200	Fixed	200	HAMD 24	37.30	4	RDC	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				amitriptyline	No	43	49.6 (11.6)	*	150-150	Fixed	150	HAMD 24	37.60								
Ansseau 1991	1991	3	3	fluvoxamine	Unclear	41	46.6 (11.6)	*	200-200	Fixed	200	HAMD 24	32.69	4	RDC	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				milnacipran	Unclear	42	49.9 (12.4)	*	150-150	Fixed	150	HAMD 24	33.94								
				milnacipran	Unclear	43	46.5 (13.3)	*	200-200	Fixed	200	HAMD 24	31.89								
Ansseau 1994a (MY-1005/BRL-029060/1/CPMS-112)	1994	2	2	paroxetine	Yes	55	43.7 (11.5)	0.46	20-30	Flexible	*	HAMD 21	26.00	6	DSM-III-R	Europe	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				fluvoxamine	No	65	43.4 (9.9)	0.67	100-200	Flexible	*	HAMD 21	26.50								
Ansseau 1994b	1994	2	2	milnacipran	Yes	97	44.8 (11.2)	*	100-100	Fixed	100	HAMD 24	30.60	6	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				fluoxetine	No	93	45 (12.3)	*	20-20	Fixed	20	HAMD 24	32.40								
Ansseau 1994c	1994	2	2	nefazodone	Yes	55	45.8 (12.6)	0.73	100-400	Flexible	242	HAMD 17	27.70	6	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Yes
				amitriptyline	No	51	48.6 (13.6)	0.67	50-200	Flexible	124	HAMD 17	28.10								
Armitage 1997	1997	2	2	nefazodone	Yes	22	37.1 (8.4)	0.50	400-500	Flexible	433	HAMD 17	23.50	8	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	No	21	37.2 (10.5)	0.76	20-40	Flexible	31	HAMD 17	23.60								

Asnis 2013 (LVM-MD-01, NCT00969709)	2013	4	4	placebo	No	179	41.3 (11.3)	0.61	0-0	Fixed	0	HAMD 17	24.60	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Yes
				levomilnacipran	Yes	181	41.6 (13.1)	0.69	40-40	Fixed	40	HAMD 17	24.70								
				levomilnacipran	Yes	181	41 (12.8)	0.62	80-80	Fixed	80	HAMD 17	24.90								
				levomilnacipran	Yes	183	40.3 (11.9)	0.59	120-120	Fixed	120	HAMD 17	25.00								
Bakish 1992	1992	2	3	amitriptyline	No	58	42 (9)	*	50-150	Flexible	112	HAMD 17	22.81	6	DSM-III-R	North America	Multi-center	Unclear	Outpatients only	Yes	Yes
				placebo	No	56	44 (10.7)	*	0-0	Flexible	0	HAMD 17	23.04								
Bakish 1997	1997	2	2	fluoxetine	No	9	39 (9)	0.62	20-80	Flexible	*	HAMD 17	22.30	12	DSM-III-R	North America	Unclear	Unclear	Other/Unclear	Unclear	Yes
				paroxetine	Yes	12	39 (9)	0.62	20-50	Flexible	*	HAMD 17	22.30								
Bakish 2014 (LVM-MD-10, NCT01377194)	2014	3	3	placebo	No	189	42.3 (13.2)	0.62	0-0	Fixed	0	MADRS	31.00	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				levomilnacipran	Yes	190	42.9 (13.4)	0.62	40-40	Fixed	40	MADRS	30.80								
				levomilnacipran	Yes	189	43.1 (12.8)	0.66	80-80	Fixed	80	MADRS	31.20								
Baldwin 1996	1996	2	2	nefazodone	Yes	105	38.3 (*)	0.60	200-600	Flexible	472	HAMD 17	24.60	8	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				paroxetine	No	101	37.9 (*)	0.50	20-40	Flexible	33	HAMD 17	24.80								
Baldwin 2006a (97-CRBX-052 - Study 052)	2006	2	2	reboxetine	Yes	159	42.4 (12.1)	0.63	8-10	Flexible	9	HAMD 17	24.20	8	DSM-IV	Europe	Multi-center	Other/Unclear	Other/Unclear	Unclear	Yes
				paroxetine	No	166	45.1 (11)	0.62	20-40	Flexible	27	HAMD 17	24.10								
Baldwin 2006b (Study 99505)	2006	2	2	paroxetine	No	159	45.1 (13.2)	*	20-40	Flexible	26	MADRS	29.70	8	DSM-III-R	Europe	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				escitalopram	Yes	166	44.9 (14.7)	*	10-20	Flexible	14	MADRS	29.60								
Baldwin 2012 (11984A, NCT00635219)	2012	4	5	placebo	No	152	43.3 (12.5)	0.70	0-0	Fixed	0	HAMD 24	29.80	8	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	Unclear	Yes
				vortioxetine	Yes	159	44.7 (13.1)	0.66	5-5	Fixed	5	HAMD 24	31.30								
				vortioxetine	Yes	153	45.2 (13.1)	0.68	10-10	Fixed	10	HAMD 24	30.40								
				duloxetine	No	157	45.3 (12)	0.68	60-60	Fixed	60	HAMD 24	29.90								
Ban 1998 (Study 008)	1998	2	3	reboxetine	Unclear	84	46.4 (11.4)	0.50	8-8	Fixed	8	HAMD 17	26.89	4	DSM-III-R	Cross-Continental	Multi-center	Secondary /Tertiary care	Inpatients only	No	Yes
				placebo	No	85	46.7 (11.8)	0.64	0-0	Fixed	0	HAMD 17	25.43								

Barber 2011	2011	2	3	sertraline	No	55	38 (12.5)	*	50-200	Fixed	200	HAMD 17	19.00	16	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	No	Unclear
				placebo	No	50	38.3 (12)	*	0-0	Fixed	0	HAMD 17	19.3								
Battegay 1985 (PAR 29060.309 HP/81/162A)	1985	2	2	paroxetine	Yes	11	41.5 (11.3)	0.55	30-30	Fixed	30	*	*	7	*	Europe	Single center	Unclear	Unclear	Unclear	Unclear
				amitriptyline	No	10	36.9 (10.8)	0.60	100-100	Fixed	100	*	*								
Beasley 1991	1991	2	2	trazodone	No	61	40 (10.8)	0.69	50-400	Flexible	244	HAMD 21	24.30	6	DSM-III	North America	Multi-center	Unclear	Outpatients only	Yes	Yes
				fluoxetine	Yes	65	40 (11.3)	0.65	20-60	Flexible	21	HAMD 21	23.40								
Behnke 2003 (E-1690, Kjernisted 2002)	2003	2	2	mirtazapine	Yes	176	42 (11)	*	30-45	Flexible	38	HAMD 17	*	8	DSM-IV	Cross-Continental	Multi-center	Both	Unclear	No	Unclear
				sertraline	No	170	41 (12)	*	50-150	Flexible	93	HAMD 17	*								
Benkert 2000 (E-1559)	2000	2	2	mirtazapine	Yes	139	47.2 (11.1)	*	15-45	Flexible	33	HAMD 17	22.40	6	DSM-IV	Europe	Multi-center	Both	Outpatients only	Yes	Unclear
				paroxetine	No	136	47.3 (10.3)	*	20-40	Flexible	23	HAMD 17	22.40								
Benkert 2006(C-1763)	2006	2	2	mirtazapine	Yes	140	46.4 (11.1)	0.56	45-45	Fixed	45	HAMD 17	24.60	6	DSM-IV	Europe	Multi-center	Unclear	Outpatients only	No	Unclear
				venlafaxine	No	135	45.1 (12.7)	0.59	225-225	Fixed	225	HAMD17	24.90								
Bennie 1995	1995	2	2	sertraline	Yes	142	49.9 (*)	*	50-100	Flexible	62	HAMD 17	23.20	6	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				fluoxetine	No	144	49.9 (*)	*	20-40	Flexible	25	HAMD 17	23.40								
Berlanga 1997	1997	2	2	nefazodone	Yes	37	41.5 (12.8)	0.78	400-500	Flexible	400	HAMD 17	25.10	8	DSM-III-R	South America	Multi-center	Unclear	Outpatients only	Unclear	Yes
				fluoxetine	No	37	39.9 (13.4)	0.76	20-40	Flexible	24	HAMD 17	23.70								
Berlanga 2006	2006	2	2	reboxetine	No	46	29.2 (6)	*	4-8	Flexible	*	HAMD 21	26.99	8	DSM-IV	South America	Single center	Secondary /Tertiary care	Outpatients only	No	No
				citalopram	Yes	55	29.65 (7.3)	*	20-40	Flexible	*	HAMD21	27.15								
Bersani 1994	1994	2	2	sertraline	Unclear	34	47.2 (12)	0.63	50-150	Flexible	88	HAMD 21	33	8	DSM-III-R	Europe	Unclear	Unclear	Outpatients only	Unclear	No
				amitriptyline	Unclear	34	46.9 (12)	0.63	50-150	Flexible	84	HAMD 21	32								
Bhatia 1991	1991	2	3	amitriptyline	No	7	38 (15.1)	*	200-300	Flexible	250	HAMD 17	32.92	6	DSM-III	North America	Multi-center	Secondary /Tertiary care	Inpatients only	No	Unclear
				placebo	No	8	45.6 (10.2)	*	0-0	Flexible	0	HAMD 17	32.92								
Bielski 2004 (SCT-MD-12)	2004	2	2	escitalopram	Yes	101	37.3 (12.3)	*	20-20	Fixed	20	HAMD 24	28.60	8	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				venlafaxine	No	101	37.5 (11.6)	*	225-225	Fixed	225	HAMD 24	27.40								

Bignamini 1992 (PAR 29060/078)	1992	2	2	paroxetine	Yes	156	49.1 (13.8)	*	20-30	Flexible	*	HAMD 21	30.50	6	DSM-III	Europe	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				amitriptyline	No	153	49.8 (11.9)	*	75-150	Flexible	*	HAMD 21	30.90								
Binnemann 2008 (NCT00143091)	2008	2	3	sertraline	Yes	43	49 (*)	*	100-100	Fixed	100	HAMD 17	23.30	6	DSM-IV	Cross-Continental	Multi-center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	39	49 (*)	*	0-0	Fixed	0	HAMD 17	23.55								
Bjerkenstedt 2005	2005	2	3	fluoxetine	No	57	50.4 (11.6)	*	20-20	Fixed	20	HAMD 21	23.80	6	DSM-IV	Europe	Multi-center	Primary care	Outpatients only	Yes	Unclear
				placebo	No	58	51.4 (11.8)	*	0-0	Fixed	0	HAMD 21	25.20								
Blacker 1988	1988	2	4	amitriptyline	No	44	42 (12.5)	*	100-100	Fixed	100	HAMD 21	26.70	6	DSM-III	Europe	Multi-center	Primary care	Outpatients only	Unclear	Unclear
				trazodone	Unclear	112	45 (12.8)	*	150-150	Fixed	150	HAMD 21	26.30								
Bosc 1997a (Study 014 - Andreoli2002)	1997	3	3	reboxetine	Yes	126	40 (12)	0.67	8-10	Flexible	*	HAMD 21	26.80	8	DSM-III-R	Cross-Continental	Multi-center	Unclear	Outpatients only	No	Yes
				placebo	No	128	44.1 (12.1)	0.54	0-0	Flexible	0	HAMD 21	27.40								
				fluoxetine	No	127	40.2 (11.5)	0.65	20-40	Flexible	*	HAMD 21	26.90								
Bosc 1997b (Study 016 - Massana 1999)	1997	2	2	reboxetine	Yes	79	44 (12.6)	0.72	8-10	Flexible	8	HAMD 21	28.60	8	DSM-III-R	Cross-Continental	Multi-center	Unclear	Both	Unclear	Yes
				fluoxetine	No	89	43.6 (11.8)	0.72	20-40	Flexible	23	HAMD 21	27.40								
Bose 2008 (SCT-MD-13)	unpublished	2	2	escitalopram	Yes	132	68.1 (6.7)	*	10-20	Flexible	*	HAMD unspecified	24.90	12	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				placebo	No	135	68.5 (7.1)	*	0-0	Flexible	0	HAMD unspecified	24.30								
Bougerol 1997 (Study 91302 - FDA)	1997	2	2	fluoxetine	No	158	41 (*)	*	20-20	Fixed	20	MADRS	31.80	8	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Other/Unclear	No	Yes
				citalopram	Yes	158	43 (*)	*	40-40	Fixed	40	MADRS	31.20								
Boulenger 2006 (Study 10351)	2006	2	2	escitalopram	Yes	232	43.8 (12.5)	*	20-20	Fixed	20	MADRS	35.20	24	DSM-IV	Europe	Multi-center	Both	Outpatients only	No	Unclear
				paroxetine	Yes	227	44.7 (13)	*	40-40	Fixed	40	MADRS	34.80								
Boulenger 2014 (13267A, NCT01140906)	2014	4	4	placebo	No	158	48.1 (13.1)	0.70	0-0	Fixed	0	MADRS	31.50	8	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	Unclear	Yes
				vortioxetine	Yes	152	47 (14.6)	0.64	15-15	Fixed	15	MADRS	31.80								
				vortioxetine	Yes	151	46.2 (13.4)	0.60	20-20	Fixed	20	MADRS	31.20								
				duloxetine	No	147	45.6 (13.6)	0.69	60-60	Fixed	60	MADRS	31.20								
Boyer 2008 (Study 333, NCT00300378)(EUCTR2005-	2008	3	3	desvenlafaxine	Yes	166	44 (14)	0.70	50-50	Fixed	50	HAMD 17	24.26	8	DSM-IV	Cross-Continental	Multi-center	Both	Outpatients only	Unclear	Unclear
				desvenlafaxine	Yes	158	46 (13)	0.71	100-100	Fixed	100	HAMD 17	24.44								

005463-28, 3151A1-333-EU)				placebo	No	161	46 (12)	0.68	0-0	Fixed	0	HAMD 17	24.29						
Bremner 1995(MIR 003-022 - FDA)	1995	3	3	amitriptyline	No	50	39 (*)	*	40-280	Flexible	187	HAMD 21	32	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	50	37 (*)	*	0-0	Flexible	0	HAMD 21	31.2								
				mirtazapine	Yes	50	39 (*)	*	5-35	Flexible	31	HAMD 21	33								
Brown 1986	1986	2	3	fluvoxamine	Unclear	33	33.4 (*)	*	200-300	Flexible	214	HAMD 21	*	6	DSM-III	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Unclear
				placebo	No	31	*	*	0-0	Flexible	0	HAMD 21	*								
Brunoni 2012	2012	2	4	sertraline	No	30	41 (12)	*	50-50	Fixed	50	MADRS	30.5	6	DSM-IV	South America	Single center	Secondary / Tertiary care	Outpatients only	No	Yes
				placebo	No	30	46.4 (14)	*	0-0	Fixed	0	MADRS	30.76								
Buchsbaum 1997	1997	2	2	sertraline	Yes	7	38.5 (12.3)	0.59	*	Other/Unclear	*	HAMD 24	32.00	10	DSM-III-R	North America	Unclear	Secondary /Tertiary care	Unclear	Yes	Unclear
				placebo	No	10	38.5 (12.3)	0.59	0-0	Other/Unclear	0	HAMD 24	29.45								
Bueno 1997	1997	2	2	nefazodone	Unclear	19	46.7 (10.5)	0.79	200-500	Flexible	*	HAMD unspecified	*	8	DSM-III-R	South America	Unclear	Unclear	Outpatients only	Yes	Unclear
				amitriptyline	Unclear	18	45.2 (12.2)	0.89	50-125	Flexible	*	HAMD unspecified	*								
Burke 2002 (SCT-MD-01)	2002	4	4	escitalopram	Yes	124	40.6 (12.3)	*	10-10	Fixed	10	HAMD unspecified	24.30	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				escitalopram	Yes	128	39.6 (12.1)	*	20-20	Fixed	20	HAMD unspecified	25.80								
				citalopram	Yes	127	40 (11.5)	*	40-40	Fixed	40	HAMD unspecified	25.90								
				placebo	No	127	40.3 (10.6)	*	0-0	Fixed	0	HAMD unspecified	25.80								
Byerley 1988	1988	2	3	placebo	No	29	37.5 (9.1)	*	0-0	Flexible	0	HAMD 21	27.40	6	DSM-III	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				fluoxetine	Yes	32	38.9 (10.7)	*	40-80	Flexible	*	HAMD 21	27.10								
CAGO178A2303 (NCT00463242)	unpublished	3	3	agomelatine	Yes	169	42.1 (13.1)	0.62	25-50	Flexible	*	HAMD 17	27.20	8	DSM-IV	North America	Multi-center	Unclear	Unclear	Unclear	Unclear
				paroxetine	No	168	43.7 (12.7)	0.59	20-40	Flexible	*	HAMD 17	27.00								
				placebo	No	166	42.9 (11.8)	0.67	0-0	Flexible	0	HAMD 17	26.90								
Caligiuri 2003	2003	2	3	bupropion	No	7	42 (9.8)	*	*	Flexible	400	HAMD 17	18.40	9	DSM-IV	North America	Single center	Secondary /Tertiary care	Outpatients only	Unclear	Unclear
				sertraline	No	9	42 (9.8)	*	50-*	Flexible	165	HAMD 17	18.40	8							

Carman 1991	1991	2	3	amitriptyline	No	50	*	*	60-300	Flexible	*	HAMD 17	27.6	6	DSM-III	North America	Unclear	Unclear	Outpatients only	Yes	Unclear
				placebo	No	50	*	*	0-0	Flexible	0	HAMD 17	26.7								
Casabona 2002 (0600B 428)	2002	2	2	paroxetine	No	56	*	*	20-20	Fixed	20	*	*	8	DSM-IV	Europe	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				venlafaxine	Yes	58	*	*	75-75	Fixed	75	*	*								
Cassano 1986	1986	2	3	fluvoxamine	Yes	161	42.7 (13.7)	*	50-300	Flexible	145	HAMD 17	25.61	4	DSM-III	Cross-Continental	Multi-center	Unclear	Both	Yes	Yes
				placebo	No	149	42.1 (11.8)	*	0-0	Flexible	0	HAMD 17	25.60								
Cassano 2002 (29060/421)	2002	2	2	paroxetine	Yes	123	75.61 (6.99)	*	20-40	Flexible	*	HAMD unspecified	22.95	6	ICD-10	Europe	Multi-center	Unclear	Outpatients only	Yes	Unclear
				fluoxetine	No	119	74.85 (6.67)	*	20-60	Flexible	*	HAMD unspecified	23.41								
Chang 2015	2015	2	2	fluoxetine	No	58	41.7 (12)	0.76	20-80	Flexible	21	HAMD 21	24.30	6	DSM-IV	Asia	Unclear	Other/Unclear	Outpatients only	Unclear	Yes
				venlafaxine	No	54	37.5 (12.5)	0.70	75-225	Flexible	80	HAMD 21	25.90								
Chouinard 1983a	1983	2	2	amitriptyline	Unclear	41	35.1 (*)	*	75-150	Flexible	119	HAMD 21	26.10	13	Other operationalized	North America	Multi-center	Unclear	Outpatients only	Yes	Yes
				bupropion	Unclear	77	38.9 (*)	*	300-450	Flexible	374	HAMD 21	26.50								
Chouinard 1985	1985	2	2	fluoxetine	Unclear	25	41 (*)	*	40-80	Flexible	69	HAMD 21	27.60	5	RDC	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				amitriptyline	Unclear	28	39 (*)	*	150-300	Flexible	163	HAMD 21	25.90								
Chouinard 1999 (29060/131)	1999	2	2	paroxetine	Yes	102	40.6 (10.7)	*	20-50	Flexible	26	HAMD 21	25.91	12	DSM-III-R	North America	Multi-center	Unclear	Unclear	Yes	Unclear
				fluoxetine	No	101	41.2 (10.7)	*	20-80	Flexible	28	HAMD 21	25.45								
Christiansen 1996	1996	2	2	paroxetine	Unclear	71	*	*	20-40	Flexible	*	HAMD 17	23.8	8	*	Europe	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				amitriptyline	Unclear	73	*	*	100-150	Flexible	*	HAMD 17	24.2								
CL3-20098-022	2001	3	3	agomelatine	Yes	133	41 (9.7)	0.67	25-25	Fixed	25	HAMD 17	27.60	24	DSM-IV	Europe	Multi-center	Secondary /Tertiary care	Both	Yes	No
				fluoxetine	no	137	42.9 (11.3)	0.67	20-20	Fixed	20	HAMD 17	27.50								
				placebo	No	149	43 (9.5)	0.67	0-0	Fixed	0	HAMD 17	28.00								
CL3-20098-023	2001	3	3	agomelatine	Yes	142	40.6 (10.8)	0.75	25-25	Fixed	25	HAMD 17	25.70	24	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	No	No
				paroxetine	No	138	40.9 (11)	0.75	20-20	Fixed	20	HAMD 17	26.10								
				placebo	No	137	41.2 (10.1)	0.75	0-0	Fixed	0	HAMD 17	26.00								

CL3-20098-024	2002	3	4	agomelatine	Yes	301	40.4 (11.1)	0.73	25-50	Fixed	38	HAMD 17	26.40	24	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	No	Unclear
				fluoxetine	No	148	41.3 (10)	0.73	20-20	Fixed	20	HAMD 17	26.50								
				placebo	No	158	41.6 (11.2)	0.73	0-0	Fixed	0	HAMD 17	26.90								
CL3-20098-026	2001	2	2	agomelatine	Yes	109	66.8 (5.3)	*	25-25	Fixed	25	HAMD 17	23.40	24	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	No	No
				placebo	No	109	67.8 (5.1)	*	0-0	Fixed	0	HAMD 17	23.00								
CL3-20098-036	2004	2	2	agomelatine	Yes	137	39.6 (10.3)	0.72	50-50	Fixed	50	MADRS	27.90	24	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	No
				venlafaxine	No	140	42.1 (10)	0.72	75-150	Flexible	*	MADRS	27.90								
CL3-20098-048	2008	2	2	agomelatine	Yes	213	68.6 (6.2)	*	25-50	Flexible	*	HAMD 17	26.30	24	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	No
				paroxetine	No	199	68.3 (6.2)	*	20-30	Flexible	*	HAMD 17	26.20								
CL3-20098-062	2010	2	2	agomelatine	Yes	202	43 (12.3)	*	25-50	Flexible	*	HAMD 17	26.20	25	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	No
				duloxetine	No	216	42.5 (11.9)	*	60-60	Fixed	60	HAMD 17	26.30								
CL3-20098-070	2011	2	2	agomelatine	Yes	151	71.9 (5.1)	*	25-50	Flexible	*	HAMD 17	26.80	24	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	No
				placebo	No	71	71.7 (4.8)	*	0-0	Flexible	0	HAMD 17	26.70								
Claghorn 1983	1983	2	3	amitriptyline	No	85	39 (12.7)	*	75-300	Flexible	180	HAMD 21	26.51	4	RDC	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	87	39.1 (12.5)	*	0-0	Flexible	0	HAMD 21	27.11								
Claghorn 1995 (MIR 003-002 (FDA)	1995	2	2	mirtazapine	Yes	45	39 (*)	*	*-35	Flexible	17	HAMD 21	24.20	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	45	40 (*)	*	0-0	Flexible	0	HAMD 21	24.70								
Claghorn 1996	1996	2	3	fluvoxamine	Yes	50	39 (10.9)	*	50-150	Flexible	93	HAMD 21	26.09	6	DSM-III-R	North America	Single center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	50	39 (10.9)	*	0-0	Flexible	0	HAMD 21	26.42	7							
Clayton 2003 (Study 050)	2003	3	3	reboxetine	Yes	150	39.8 (11.4)	0.63	8-10	Flexible	10	HAMD 21	25.60	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Yes
				placebo	No	150	39.8 (11.1)	0.60	0-0	Flexible	0	HAMD 21	25.50								
				fluoxetine	No	150	40.7 (10.6)	0.66	20-40	Flexible	36	HAMD 21	26.00								
Clayton 2006a (WELL AK130926)	2006	3	3	bupropion	Yes	138	37 (12.5)	*	300-450	Flexible	309	HAMD 17	*	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Yes
				escitalopram	Unclear	149	35.7 (12.1)	*	10-20	Flexible	13	HAMD 17	*								
				placebo	No	137	37 (10.7)	*	0-0	Flexible	0	HAMD 17	*								

Clayton 2006b (WELL AK130927)	2006	3	3	escitalopram	Unclear	138	35.4 (10.4)	*	10-20	Flexible	13	HAMD 17	23.80	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Yes
				bupropion	Yes	141	36.5 (12.2)	*	300-450	Flexible	323	HAMD 17	24.50								
				placebo	No	141	35.1 (11.8)	*	0-0	Flexible	0	HAMD 17	24.40								
Clayton 2013 (NCT01121484)	2013	2	2	desvenlafaxine	Yes	218	53.2 (6.8)	1.00	50-50	Fixed	50	HAMD 17	22.8	8	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	No	Yes
				placebo	No	221	52.8 (6.6)	1.00	0-0	Fixed	0	HAMD 17	22.4								
Clayton 2015	2015	3	3	placebo	No	306	41.7 (12.4)	0.58	0-0	Fixed	0	HAMD 17	23.6	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				desvenlafaxine	Yes	306	41.8 (13.6)	0.57	50-50	Fixed	50	HAMD 17	23.4								
				desvenlafaxine	Yes	312	41.3 (12.8)	0.53	100-100	Fixed	100	HAMD 17	23.5								
Clerc 1994	1994	2	2	fluoxetine	No	34	53.6 (*)	*	40-40	Fixed	40	HAMD 21	29.70	6	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Unclear
				venlafaxine	Yes	34	49 (*)	*	200-200	Fixed	200	HAMD 21	29.10								
Clerc 2001	2001	2	2	fluvoxamine	No	56	52.2 (12.6)	*	200-200	Fixed	200	HAMD 24	31.40	6	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Both	Yes	Yes
				milnacipran	Yes	57	48.7 (15.1)	*	100-100	Fixed	100	HAMD 24	32.80								
CN104-002 (FDA)	unpublished	2	3	nefazodone	Yes	60	38.2 (*)	0.57	50-300	Flexible	263	HAMD 17	23.30	6	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				placebo	No	60	38.6 (*)	0.65	0-0	Flexible	0	HAMD 17	23.10								
CN104-045 (FDA)	unpublished	2	2	nefazodone	Yes	*	*	0.63	100-400	Other/Unclear	*	*	*	6	Unclear	North America	Multi-center	Unclear	Outpatients	Unclear	Unclear
				placebo	No	*	*	0.63	0-0	Other/Unclear	0	*	*								
CN104-054 (FDA)	unpublished	3	3	nefazodone	Yes	*	*	0.68	100-600	Fixed	*	*	*	8	Unclear	North America	Multi-center	Unclear	Outpatients	Unclear	Unclear
				fluoxetine	No	*	*	0.68	20-20	Fixed	20	*	*								
				placebo	No	*	*	0.68	0-0	Fixed	0	*	*								
Cohn 1985a	1985	2	3	fluoxetine	Yes	54	41 (*)	0.72	20-80	Flexible	*	HAMD unspecified	25.75	6	DSM-III	North America	Single center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	58	44 (*)	0.48	0-0	Flexible	0	HAMD unspecified	25.14								
Cohn 1990	1990	2	2	sertraline	Unclear	161	70.2 (*)	0.50	50-200	Flexible	116	HAMD 17	23.7	8	DSM-III	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				amitriptyline	No	80	70.6 (*)	0.46	50-150	Flexible	88	HAMD 17	25.2								
Cohn 1996 (FDA CN104-006-2)	1996	2	3	nefazodone	Yes	43	39.4 (13.1)	0.77	200-600	Flexible	321	HAMD 17	22.80	8	DSM-III-R	North America	Single center	Unclear	Outpatients only	Unclear	No
				placebo	No	43	38.8 (12.5)	0.64	0-0	Flexible	0	HAMD 17	23.40								

Coleman 1999 (AK1A4002)	1999	3	3	sertraline	No	118	38.3 (11.7)	*	50-200	Flexible	106	HAMD 31	34.80	8	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	No
				placebo	No	124	38.5 (10.6)	*	0-0	Flexible	0	HAMD 31	34.00								
				bupropion	Yes	122	38.1 (10.4)	*	150-400	Flexible	290	HAMD 31	34.50								
Coleman 2001 (AK1A4007)	2001	3	3	fluoxetine	No	154	37.1 (10.6)	*	20-60	Flexible	26	HAMD 21	24.50	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	No	Unclear
				bupropion	Yes	150	36.6 (10.5)	*	150-400	Flexible	319	HAMD 21	24.60								
				placebo	No	152	36.7 (10.7)	*	0-0	Flexible	0	HAMD 21	24.40								
Colonna 2005 (Study 99022)	2005	2	2	escitalopram	Yes	175	46 (12)	*	10-10	Fixed	10	MADRS	29.50	8	DSM-IV	Europe	Multi-center	Primary care	Outpatients only	Yes	Unclear
				citalopram	No	182	46 (11)	*	20-20	Fixed	20	MADRS	30.20								
Corrigan 2000	2000	2	5	fluoxetine	No	35	42 (*)	*	20-20	Fixed	20	HAMD 17	22.00	8	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Unclear	Yes	Unclear
				placebo	No	35	42 (*)	*	0-0	Fixed	0	HAMD 17	20.80								
Corruble 2013 (CL3-20098-063)	2008	2	2	agomelatine	Yes	164	43.6 (12.9)	0.73	25-50	Flexible	*	HAMD 17	26.80	25	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	No
				escitalopram	No	160	42.8 (11.8)	0.69	10-20	Flexible	*	HAMD 17	26.60								
Costaesilva 1998	1998	2	2	fluoxetine	No	186	39.8 (10.3)	*	20-40	Flexible	*	HAMD 17	29.70	8	DSM-III-R	South America	Multi-center	Unclear	Outpatients only	No	Unclear
				venlafaxine	Yes	196	40.5 (10.7)	*	75-150	Flexible	*	HAMD 17	30.40								
Croft 1999 (AK1A4001)	1999	3	3	sertraline	No	119	36 (9.8)	*	50-200	Flexible	121	HAMD 29	33.10	8	DSM-IV	North America	Multi-center	Unclear	Unclear	No	No
				bupropion	Yes	120	35.9 (10.8)	*	150-400	Flexible	293	HAMD 29	32.90								
				placebo	No	121	37.4 (10.9)	*	0-0	Flexible	0	HAMD 29	32.20								
Croft 2014 (NCT01473394)	2014	2	2	vilazodone	Yes	260	39.3 (12.8)	0.51	40-40	Fixed	40	MADRS	30.60	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	No	Yes
				placebo	No	258	41.1 (13.2)	0.56	0-0	Fixed	0	MADRS	30.90								
Cunningham 1994 (VEN 600A-302 FDA)	1994	3	3	venlafaxine	Yes	76	42 (*)	0.63	75-200	Flexible	160	HAMD 21	25.02	6	DSM-III-R	North America	Multi-center	Unclear	Outpatients only	Yes	Yes
				trazodone	No	77	39 (*)	0.69	150-400	Flexible	300	HAMD 21	24.66								
				placebo	No	76	41 (*)	0.67	0-0	Flexible	0	HAMD 21	24.41								
Cunningham 1997 (VEN XR 208 - FDA)	1997	3	3	venlafaxine	Yes	97	39.7 (11)	0.63	75-150	Flexible	139	HAMD 21	24.40	12	DSM-III-R	North America	Multi-center	Unclear	Outpatients only	Yes	Yes
				venlafaxine	Yes	96	42.8 (11.4)	0.67	75-150	Flexible	123	HAMD 21	23.98								
				placebo	No	100	39.9 (10.1)	0.59	0-0	Flexible	0	HAMD 21	24.56								

Cutler 2009	2009	2	3	duloxetine	No	151	40.2 (12.5)	*	60-60	Fixed	60	HAMD 17	25.20	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Yes
				placebo	No	157	42.3 (11.5)	*	0-0	Fixed	0	HAMD 17	25.20								
Dalery 2003	2003	2	2	fluvoxamine	Yes	90	42 (*)	*	100-100	Fixed	100	HAMD 17	22.30	6	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				fluoxetine	No	94	42.1 (*)	*	20-20	Fixed	20	HAMD 17	22.20								
D'Amico 1990 (FDA 030-A2-0007)	1990	3	5	nefazodone	Yes	47	*	*	200-200	Fixed	200	HAMD 17	26.10	6	RDC	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				nefazodone	Yes	47	*	*	300-300	Fixed	300	HAMD 17	25.40								
				placebo	No	47	*	*	0-0	Fixed	0	HAMD 17	26.40								
Davidson 2002 (HDTSG) (NCT00005013)	2002	2	3	sertraline	Unclear	111	43.9 (13.9)	0.67	50-100	Flexible	75	HAMD 17	22.50	8	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	116	40.1 (12.2)	0.66	0-0	Flexible	0	HAMD 17	22.70								
Debonnel 2000 (Blier 2009, iQWIG E-1639)	2009	2	3	mirtazapine	Yes	21	45.9 (9.1)	0.29	30-45	Flexible	*	HAMD 17	24.00	6	DSM-IV	North America	Single center	Unclear	Unclear	Yes	Yes
				paroxetine	No	21	39.7 (11.8)	0.48	20-30	Flexible	*	HAMD 17	24.20								
Debus 1988	1988	2	2	fluoxetine	Yes	22	35.4 (8.6)	*	20-60	Flexible	31	HAMD 21	23.40	6	DSM-III	North America	Multi-center	Both	Outpatients only	Yes	No
				trazodone	No	21	39.3 (8.3)	*	50-400	Flexible	305	HAMD 21	25.20								
DeMartinis 2007 (Study 306, NCT00072774)	2007	2	4	placebo	No	120	40 (12.8)	0.68	0-0	Fixed	0	HAMD 17	23.1	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				desvenlafaxine	Yes	118	40.4 (12.1)	0.65	100-100	Fixed	100	HAMD 17	23.2								
Demyttenaere 1998	1998	2	2	amitriptyline	No	31	42.1 (8.1)	*	150-150	Fixed	150	HAMD unspecified	23.90	9	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Unclear
				fluoxetine	Yes	35	41.4 (8.9)	*	20-20	Fixed	20	HAMD unspecified	24.90								
DeRonchi 1998	1988	2	2	fluoxetine	Unclear	32	69.1 (5.92)	*	20-20	Fixed	20	HAMD 17	25.60	10	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				amitriptyline	Unclear	33	68.6 (7.64)	*	50-100	Fixed	100	HAMD 17	26.50								
Detke 2002a (HMBH - Study Group A)	2002	2	2	duloxetine	Yes	123	42.44 (13.7)	*	60-60	Fixed	60	HAMD 17	21.50	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	122	42.34 (12.6)	*	0-0	Fixed	0	HAMD 17	21.09								
Detke 2002b (HMBH - Study Group B)	2002	2	2	duloxetine	Yes	128	40.83 (12.6)	*	60-60	Fixed	60	HAMD 17	20.28	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	139	41.04 (14.7)	*	0-0	Fixed	0	HAMD 17	20.49								
Detke 2004 (HMAY Study Group A)	2004	4	4	duloxetine	Yes	95	43.09 (11.1)	*	80-80	Fixed	80	HAMD 17	19.88	8	DSM-IV	Unspecified	Multi-center	Unclear	Outpatients only	Yes	Unclear
				duloxetine	Yes	93	44.72 (10.7)	*	120-120	Fixed	120	HAMD 17	20.17								

				paroxetine	No	86	42 (10.6)	*	20-20	Fixed	20	HAMD 17	20.26							
				placebo	No	93	43.67 (12.2)	*	0-0	Fixed	0	HAMD 17	19.86							
Deushle 2003 (NCT01049347)	2003	2	2	amitriptyline	No	14	49.5 (17.5)	0.64	150-150	Fixed	150	HAMD unspecified	21.64	5	DSM-IV	Europe	Unclear	nclear	Inpatients only	Unclear	Yes
				paroxetine	No	21	61.2 (13)	0.67	40-40	Fixed	40	HAMD unspecified	23.62							
DeWilde 1983a	1983	2	2	fluvoxamine	Yes	22	*	*	100-300	Flexible	300	HAMD 17	23.40	6	Feighner	Europe	Single center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				clomipramine	No	21	*	*	50-150	Flexible	144	HAMD 17	24.20							
DeWilde 1993	1993	2	2	paroxetine	Yes	49	43.9 (13.2)	*	20-40	Flexible	*	HAMD 21	27.00	6	DSM-III	Europe	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				fluoxetine	No	50	44.3 (12)	*	20-60	Flexible	*	HAMD 21	28.20							
Dierick 1996	1996	2	2	fluoxetine	No	161	43.2 (13)	0.64	20-20	Fixed	20	HAMD 17	26.60	8	DSM-III-R	Europe	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				venlafaxine	Yes	153	43.7 (12.5)	0.65	75-150	Flexible	112	HAMD 17	27.00							
Dimidjian 2006	2006	2	4	paroxetine	No	100	39.9 (*)	0.68	*-50	Flexible	32	HAMD 17	20.87	16	DSM-IV	North America	Unclear	Secondary /Tertiary care	Outpatients only	No	Unclear
				placebo	No	53	39.9 (*)	0.72	0-0	Flexible	0	HAMD 17	21.15							
Dominguez 1985	1985	2	3	fluvoxamine	Unclear	35	*	*	100-300	Flexible	*	HAMD 17	20.40	4	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	31	*	*	0-0	Flexible	0	HAMD 17	20.90							
Doogan 1994	1994	2	3	sertraline	Yes	99	46 (*)	0.71	50-100	Flexible	62	MADRS	27.9	6	DSM-III-R	Europe	Multi-center	Primary care	Outpatients only	Yes	Yes
				placebo	No	101	45.4 (*)	0.64	0-0	Flexible	0	MADRS	27.4							
DUAG 1990	1990	2	2	paroxetine	Unclear	62	*	*	30-30	Fixed	30	HAMD 17	23.12	6	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				clomipramine	Unclear	58	*	*	150-150	Fixed	150	HAMD 17	23.36							
Dube 2010 (NCT00420004)	2010	2	3	escitalopram	No	62	34.3 (9.7)	0.36	10-20	Flexible	15	HAMD21	*	8	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				placebo	No	138	37.5 (11)	0.47	0-0	Flexible	0	HAMD 21	*							
Dunbar 1993a (Claghorn 1992, Rickels 1989, Rickels 1992, PAR 02-001 - FDA)	1993	2	2	paroxetine	Yes	55	43.4 (*)	0.69	20-50	Flexible	*	HAMD 21	26.80	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	56	46 (*)	0.59	0-0	Flexible	0	HAMD 21	25.90							
Dunbar 1993b (Claghorn 1992,	1993	2	2	paroxetine	Yes	36	34.5 (*)	0.41	20-50	Flexible	*	HAMD 21	25.00	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear

PAR 02-002 - FDA)				placebo	No	36	35.7 (*)	0.39	0-0	Flexible	0	HAMD 21	24.60							
Dunbar 1993c (Smith 1992, PAR 02-003 - FDA)	1993	2	2	paroxetine	Yes	39	44.9 (*)	0.46	20-50	Flexible	*	HAMD 21	28.60	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	38	44.6 (*)	0.55	0-0	Flexible	0	HAMD 21	28.90							
Dunbar 1993d (Kiev 1992, PAR 02-004 - FDA)	1993	2	2	paroxetine	Yes	40	34.9 (*)	0.41	20-50	Flexible	*	HAMD 21	28.80	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	41	40.3 (*)	0.50	0-0	Flexible	0	HAMD 21	27.50							
Dunlop 2011 (NCT00824291)	2011	2	2	desvenlafaxine	Yes	291	43.2 (11.7)	0.66	50-50	Fixed	50	HAMD 17	22	12	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				placebo	No	146	41.6 (12.6)	0.66	0-0	Fixed	0	HAMD 17	21.8							
Dunner 1992 (PAR 29060.09)	1992	4	5	paroxetine	Yes	106	41.6 (*)	*	20-20	Fixed	20	HAMD 21	25.19	6	DSM-III	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				paroxetine	Yes	104	41.6 (*)	*	30-30	Fixed	30	HAMD 21	25.18							
				paroxetine	Yes	106	41.4 (*)	*	40-40	Fixed	40	HAMD 21	25.03							
				placebo	No	53	40.9 (*)	*	0-0	Fixed	0	HAMD 21	24.50							
E-1569	unpublished	2	2	mirtazapine	Yes	73	46.5 (12.5)	0.68	30-45	Flexible	*	HAMD 17	24.60	6	DSM-IV	Europe	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				paroxetine	No	75	43 (12.5)	0.69	20-40	Flexible	*	HAMD 17	25.70							
Edwards 1989 (MD/PAR/009 PAR-276)	1989	2	2	paroxetine	Yes	21	45.1 (*)	0.55	30-30	Fixed	30	HAMD 17	26.80	6	DSM-III	Europe	Single center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				placebo	No	21	43.3 (*)	0.57	0-0	Fixed	0	HAMD 17	25.50							
Ekselius 1997	1997	2	2	citalopram	No	200	48.1 (12)	*	20-60	Flexible	34	MADRS	28.30	12	DSM-III-R	Europe	Multi-center	Primary care	Outpatients only	Yes	No
				sertraline	Yes	200	47.3 (13.3)	*	50-150	Flexible	82	MADRS	28.30							
Faber 1995 (SER 103 FDA)	1995	4	4	sertraline	Yes	95	37 (*)	0.51	50-50	Fixed	50	HAMD17	24.80	6	DSM-III	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				sertraline	Yes	92	37 (*)	0.57	100-100	Fixed	100	HAMD 17	24.90							
				sertraline	Yes	91	38 (*)	0.63	200-200	Fixed	200	HAMD 17	25.70							
				placebo	No	91	37 (*)	0.44	0-0	Fixed	0	HAMD 17	25.30							
Fabre 1979	1979	2	3	trazodone	Yes	13	*	*	200-300	Flexible	287	HAMD unspecified	*	4	Other operationalized	North America	Unclear	Secondary /Tertiary care	Unclear	Yes	Yes
				placebo	No	11	*	*	0-0	Flexible	0	HAMD unspecified	*							

Fabre 1996	1996	2	3	fluvoxamine	Yes	50	45 (*)	*	50-150	Flexible	119	HAMD 21	27.70	6	DSM-III-R	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	50	41 (*)	*	0-0	Flexible	0	HAMD 21	26.00								
Falk 1989	1989	2	2	trazodone	No	13	67.5 (4)	*	50-400	Flexible	350	HAMD 21	26.17	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				fluoxetine	Yes	14	69.1 (6.2)	*	20-60	Flexible	48	HAMD 21	23.77								
Fang 1997 (Yu 1997)	1997	2	2	fluoxetine	Unclear	11	36 (8)	0.55	20-20	Fixed	20	HAMD17	33	6	Other operationalized	Asia	Single center	Secondary /Tertiary care	Inpatients only	No	Unclear
				amitriptyline	Unclear	12	34 (13)	0.58	25-75	Other	*	HAMD 17	34								
Fava 1998	1998	3	3	paroxetine	Yes	55	41.3 (12.6)	*	20-50	Flexible	*	HAMD 21	23.10	12	DSM-III-R	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				fluoxetine	No	54	41.3 (12.6)	*	20-80	Flexible	*	HAMD 21	23.90								
				placebo	No	19	41.3 (12.6)	*	0-0	Flexible	0	HAMD 21	23.70								
Fava 2002	2002	3	3	sertraline	No	96	44 (14.7)	*	50-200	Flexible	108	HAMD 17	21.00	10	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				fluoxetine	Yes	92	42.1 (13.5)	*	20-60	Flexible	42	HAMD 17	20.50								
				paroxetine	No	96	42.5 (14.7)	*	20-60	Flexible	37	HAMD 17	20.60								
Fava 2005	2005	2	3	placebo	No	43	37.8 (12)	*	0-0	Fixed	0	HAMD 17	19.90	12	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				fluoxetine	No	47	36.7 (9.6)	*	20-20	Fixed	20	HAMD 17	19.60								
Fawcett 1989	1989	2	2	amitriptyline	No	20	44.5 (10.3)	*	50-200	Flexible	*	HAMD 21	23.50	6	DSM-III	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				fluoxetine	Yes	20	39.9 (10.6)	*	20-60	Flexible	*	HAMD 21	23.60								
Feiger 1996	1996	2	2	nefazodone	Yes	78	44.5 (11.5)	0.55	100-600	Flexible	456	HAMD 17	23.30	6	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Yes
				sertraline	No	82	43.1 (10)	0.48	50-200	Flexible	148	HAMD 17	23.30								
Feighner 1979	1979	2	4	amitriptyline	No	93	40.9 (*)	*	100-150	Flexible	115	HAMD 24	36	4	Feighner	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	50	40.9 (*)	*	0-0	Flexible	0	HAMD 24	34.7								
Feighner 1980	1980	2	3	trazodone	Yes	19	*	0.65	200-600	Flexible	313	HAMD unspecified	35.40	4	Feighner	North America	Unclear	Secondary /Tertiary care	Inpatients only	Yes	Unclear
				placebo	No	10	*	0.60	0-0	Flexible	0	HAMD unspecified	36.00								

Feighner 1984	1984	2	2	bupropion	Yes	45	43.9 (*)	*	300-600	Flexible	392	HAMD 21	31.00	4	Feighner	North America	Unclear	Secondary /Tertiary care	Inpatients only	No	Yes
				placebo	No	22	49 (*)	*	0-0	Flexible	0	HAMD 21	28.00								
Feighner 1989a	1989	2	3	placebo	No	59	39.7 (*)	*	0-0	Flexible	0	HAMD 21	25.90	6	DSM-III	North America	Single center	Unclear	Outpatients only	Yes	Unclear
				fluoxetine	Unclear	62	45 (*)	*	*-80	Flexible	*	HAMD 21	25.60								
Feighner 1989b	1989	2	3	fluvoxamine	Unclear	31	41 (*)	*	150-300	Flexible	145	HAMD unspecified	25.00	6	DSM-III	North America	Unclear	Secondary /Tertiary care	Inpatients only	No	Unclear
				placebo	No	19	41 (*)	*	0-0	Flexible	0	HAMD unspecified	25.00								
Feighner 1991	1991	2	2	fluoxetine	No	62	42.9 (*)	*	20-80	Flexible	38	HAMD 17	26.10	6	DSM-III-R	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				bupropion	Yes	61	40.9 (*)	*	225-450	Flexible	382	HAMD 17	25.30								
Feighner 1993a (Feighner 1989c PAR 03 001 - FDA)	1993	2	3	paroxetine	Yes	40	42.6 (*)	0.56	10-50	Flexible	26	HAMD 21	24.80	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	40	42.3 (*)	0.55	0-0	Flexible	0	HAMD 21	24.70								
Feighner 1993b (Cohn 1990 Cohn 1992 PAR 03 002 - FDA)	1993	2	3	paroxetine	Yes	40	42.3 (*)	0.69	10-50	Flexible	31	HAMD 21	25.60	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	40	41.3 (*)	0.47	0-0	Flexible	0	HAMD 21	26.70								
Feighner 1993c (PAR 03 003 - FDA)	1993	2	3	paroxetine	Yes	41	39.8 (*)	0.61	10-50	Flexible	*	HAMD 21	25.60	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	42	41.3 (*)	0.65	0-0	Flexible	0	HAMD 21	26.70								
Feighner 1993d (Shrivastava 1992 PAR 03 004 - FDA)	1993	2	3	paroxetine	Yes	40	38 (*)	0.33	10-50	Flexible	40	HAMD 21	27.60	6	DSM-III	North America	Single center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	40	34.6 (*)	0.39	0-0	Flexible	0	HAMD 21	26.70								
Feighner 1993e (Peselow 1989 PAR 03 005 - FDA)	1993	2	3	paroxetine	Yes	40	43.5 (*)	0.41	10-50	Flexible	38	HAMD 21	25.60	6	DSM-III	North America	Single center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	42	44.7 (*)	0.24	0-0	Flexible	0	HAMD 21	26.70								
Feighner 1993f (Fabre 1992 PAR 03 006 - FDA)	1993	2	3	paroxetine	Yes	40	35.6 (*)	0.55	10-50	Flexible	35	HAMD 21	29.70	6	DSM-III	North America	Single center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	40	35.9 (*)	0.64	0-0	Flexible	0	HAMD 21	28.80								
Feighner 1998	1998	2	2	nefazodone	Yes	61	37.2 (11.7)	0.61	400-600	Flexible	503	HAMD 17	27.50	6	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Yes
				placebo	No	59	39.5 (12.3)	0.63	0-0	Flexible	0	HAMD 17	27.90								
Feighner 1999 (Study 91206 FDA)	1999	4	5	citalopram	Yes	130	39 (*)	0.66	20-20	Fixed	20	HAMD 21	24.24	6	DSM-III-R	North America	Multi-center	Unclear	Outpatients only	Yes	Yes
				citalopram	Yes	131	39 (*)	0.60	40-40	Fixed	40	HAMD 21	24.44								
				citalopram	Yes	129	38 (*)	0.53	60-60	Fixed	60	HAMD 21	24.52								

				placebo	No	129	38 (*)	0.55	0-0	Fixed	0	HAMD 21	24.62						
Fontaine 1994 (FDA 03A0A-003)	1994	3	4	nefazodone	Yes	46	39.9 (10.9)	0.61	50-250	Flexible	242	HAMD 17	25.20	6	RDC	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				nefazodone	Yes	44	43.3 (10.6)	0.73	100-500	Flexible	460	HAMD 17	25.60								
				placebo	No	45	42.2 (10.7)	0.67	0-0	Flexible	0	HAMD 17	25.90								
Frank 2004	2004	2	2	citalopram	Yes	8	39.12 (6.7)	0.25	20-20	Fixed	20	*	*	4	DSM-IV	North America	Single center	Secondary /Tertiary care	Outpatients only	No	Unclear
				placebo	No	8	41.5 (7.1)	0.75	0-0	Fixed	0	*	*								
Fudge 1990	1990	2	2	fluoxetine	Unclear	21	*	*	20-60	Flexible	*	HAMD unspecified	23.20	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				trazodone	Unclear	17	*	*	50-400	Flexible	*	HAMD unspecified	23.60								
Gagiano 1993	1993	2	2	paroxetine	Yes	45	37.8 (12.5)	*	20-40	Flexible	*	HAMD 21	25.00	6	DSM-III	Africa	Single center	Unclear	Outpatients only	Yes	Unclear
				fluoxetine	No	45	39.6 (11.7)	*	20-60	Flexible	*	HAMD 21	24.50								
Gastpar 2006	2006	2	3	citalopram	No	127	49.3 (10.7)	0.65	20-20	Fixed	20	HAMD unspecified	21.80	6	DSM-IV	Europe	Multi-center	Primary care	Outpatients only	Unclear	Unclear
				placebo	No	130	49.4 (12.7)	0.73	0-0	Fixed	0	HAMD unspecified	22.00								
Gelenberg 1990	1990	2	3	amitriptyline	No	19	*	*	50-350	Flexible	114	HAMD 21	24.84	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	22	*	*	0-0	Flexible	0	HAMD 21	23.6								
Gentil 2000	2000	2	2	venlafaxine	Yes	57	37.9 (10.1)	*	75-150	Flexible	103	HAMD 21	23.90	8	DSM-IV	South America	Multi-center	Unclear	Outpatients only	Yes	Yes
				amitriptyline	No	59	39.1 (8.7)	*	75-150	Flexible	103	HAMD 21	24.50								
Georgotas 1982	1981	2	3	amitriptyline	No	15	36.1 (2.84)	*	150-300	Flexible	206	HAMD 21	28.5	4	RDC	North America	Unclear	Unclear	Other/Unclear	Unclear	Unclear
				placebo	No	18	39.5 (3.11)	*	0-0	Flexible	0	HAMD 21	28.6								
Geretsegger 1995 (MY-060/BRL-029060/1)	1995	2	2	paroxetine	Yes	44	71 (*)	*	20-30	Flexible	*	HAMD 21	26.80	6	DSM-III	Europe	Multi-center	Unclear	Inpatients only	No	Unclear
				amitriptyline	No	47	71.3 (*)	*	100-150	Flexible	*	HAMD 21	28.30								
Gerner 1980	1980	2	3	trazodone	Yes	19	68.4 (*)	0.62	100-400	Flexible	305	HAMD unspecified	27.38	4	RDC	North America	Unclear	Unclear	Outpatients only	Unclear	Unclear
				placebo	No	20	68.4 (*)	0.62	0-0	Flexible	0	HAMD unspecified	25.00								
Gillin 1997	1997	2	2	nefazodone	Yes	24	35.3 (8.8)	0.67	400-500	Flexible	435	HAMD 17	22.90	8	DSM-III-R	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	No	20	36.7 (8.5)	0.70	20-40	Flexible	34	HAMD 17	23.20								
Ginestet 1989	1989	2	2	fluoxetine	Unclear	28	46.5 (10.8)	0.71	20-80	Flexible	58	HAMD 21	33.10	8	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Yes

				clomipramine	No	26	51.6 (11)	0.73	50-200	Flexible	148	HAMD 21	33.70							
Golden 2002a (29060/448)	2002	3	3	paroxetine	Yes	106	38.9 (10.6)	*	25-62.5	Flexible	*	HAMD 17	23.00	12	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				paroxetine	Yes	106	39.4 (10.7)	*	20-50	Flexible	*	HAMD 17	23.30								
				placebo	No	103	38.7 (9.91)	*	0-0	Flexible	0	HAMD 17	23.40								
Golden 2002b (29060/449)	2002	3	3	paroxetine	Yes	108	42.38 (10.8)	*	25-62.5	Flexible	*	HAMD 17	23.80	12	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				paroxetine	Yes	112	40.55 (12.1)	*	20-50	Flexible	*	HAMD 17	23.70								
				placebo	No	110	40.71 (11.6)	*	0-0	Flexible	0	HAMD 17	23.50								
Goldstein 2002 (HMAQ - Study Group A)	2002	3	3	duloxetine	Yes	70	42.33 (10.8)	*	40-120	Flexible	*	HAMD 17	18.47	10	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	70	41.35 (13.2)	*	0-0	Flexible	0	HAMD 17	19.44								
				fluoxetine	No	33	39.69 (10.5)	*	20-20	Flexible	*	HAMD 17	17.88								
Goldstein 2004a (HMAT - Study Group A, ID#4091)	2004	4	4	duloxetine	Yes	91	43.36 (15.3)	*	40-40	Fixed	40	HAMD 17	17.47	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				duloxetine	Yes	84	43.68 (14.1)	*	80-80	Fixed	80	HAMD 17	17.44								
				placebo	No	90	43.18 (14.5)	*	0-0	Fixed	0	HAMD 17	17.79								
				paroxetine	Yes	89	44.43 (14.7)	*	20-20	Fixed	20	HAMD 17	17.97								
Goldstein 2004b (HMAT - Study Group B, ID#4091)	2004	4	4	duloxetine	Yes	86	40.69 (10.0)	*	40-40	Fixed	40	HAMD 17	18.63	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				duloxetine	Yes	91	40.89 (11.9)	*	80-80	Fixed	80	HAMD 17	18.06								
				placebo	No	89	40.14 (12.9)	*	0-0	Fixed	0	HAMD 17	17.19								
				paroxetine	No	87	40.25 (11.0)	*	20-20	Fixed	20	HAMD 17	17.65								
Gommoll 2014 (LVM-MD-02, NCT00969150)	2014	2	2	placebo	No	182	43.7 (13.3)	0.64	0-0	Flexible	0	HAMD 17	24.40	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				levomilnacipran	Yes	175	42.8 (12.9)	0.57	40-120	Flexible	93	HAMD 17	24.90								
Goodarzi 2015(IRCT2012101811155N1)	2015	2	2	mirtazapine	Unclear	24	38 (5.47)	0.79	30-30	Fixed	30	HAMD unspecified	30.58	8	DSM-IV	Asia	Multi-center	Secondary /Tertiary care	Both	Unclear	Unclear
				citalopram	Unclear	28	40.35 (10.2)	0.89	40-40	Fixed	40	HAMD unspecified	28.85								
Gorman 2002 (SCT-MD-02)	2002	3	3	escitalopram	Yes	129	41.4 (11.9)	*	10-20	Flexible	*	HAMD unspecified	24.80	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				citalopram	Yes	128	42.1 (12.7)	*	20-40	Flexible	*	HAMD unspecified	25.00								
				placebo	No	129	42.2 (12.5)	*	0-0	Flexible	0	HAMD unspecified	25.00								
Griebel 2012 (Study DF15878) (NCT00358631)	2012	2	4	escitalopram	No	84	40.8 (10.7)	0.62	10-10	Fixed	10	HAMD 17	23.40	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	76	41.2 (12.4)	0.63	0-0	Fixed	0	HAMD 17	23.00								

Griebel 2012b (Study DF15879) (NCT00361491)	2012	2	4	paroxetine	No	80	40 (13.2)	0.70	20-20	Fixed	20	HAMD 17	24.90	8	DSM-IV	Cross-Continental	Multi-center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	79	40.1 (10.6)	0.73	0-0	Fixed	0	HAMD 17	24.80								
Grunebaum 2011 (NCT00429169)	2011	2	2	bupropion	Yes	40	37.9 (11.9)	*	300-450	Flexible	275	HAMD 17	17.60	24	DSM-IV	North America	Single center	Secondary /Tertiary care	Both	No	Yes
				paroxetine	Yes	38	35.2 (12.8)	*	37.5-50	Flexible	34	HAMD 17	16.90								
GSK14	unpublished	2	2	bupropion	Yes	77	45.9 (*)	*	300-600	Flexible	*	HAMD 21	31.20	4	DSM-III	North America	Multi-center	Unclear	Inpatients only	No	Unclear
				placebo	No	40	48.2 (*)	*	0-0	Flexible	0	HAMD 21	30.30								
Guelfi 1995 (VEN 600A-206 FDA)	1995	2	2	venlafaxine	Yes	46	56 (14)	*	150-375	Flexible	350	HAMD 21	28.20	4	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				placebo	No	47	56 (13)	*	0-0	Flexible	0	HAMD 21	28.60								
Guelfi 1998	1998	3	3	milnacipran	Yes	100	45.6 (12.4)	*	100-100	Fixed	100	HAMD 17	27.90	12	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				milnacipran	Yes	100	45.2 (12.5)	*	200-200	Fixed	200	HAMD 17	27.70								
				fluoxetine	No	100	45.8 (12.8)	*	20-20	Fixed	20	HAMD 17	27.40								
Guillibert 1989 (PAR 290 MDF 29060 1727 M)	1989	2	2	clomipramine	No	39	68.1 (6.1)	*	75-75	Fixed	75	HAMD 21	27.50	6	DSM-III	Europe	Multi-center	Unclear	Unclear	Yes	Yes
				paroxetine	Yes	40	69.3 (5.3)	*	30-30	Fixed	30	HAMD 21	27.90								
Hackett 1998	1998	2	2	fluvoxamine	No	34	*	*	200-200	Fixed	200	MADRS	31.60	6	DSM-III-R	Europe	Multi-center	Unclear	Outpatients only	No	Unclear
				venlafaxine	Yes	77	*	*	150-150	Fixed	150	MADRS	32.20								
Hale 2010 (CL3-20098-045)	2008	2	2	agomelatine	Yes	252	41.8 (11.2)	0.77	25-50	Flexible	*	HAMD 17	28.50	24	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	No
				fluoxetine	No	263	42.7 (11.9)	0.78	20-40	Flexible	*	HAMD 17	28.70								
Halikas 1995 (MIR 003-023 - FDA)	1995	3	3	mirtazapine	Yes	50	63 (*)	0.43	5-35	Flexible	29	HAMD 21	24.60	6	DSM-III	North America	Unclear	Unclear	Outpatients only	Yes	Yes
				trazodone	No	50	61 (*)	0.60	40-280	Flexible	220	HAMD 21	24.60								
				placebo	No	50	62 (*)	0.59	0-0	Flexible	0	HAMD 21	23.50								
Hao 2014	2014	2	2	duloxetine	Yes	140	38.4 (13)	0.56	60-60	Fixed	60	HAMD 17	23.70	6	DSM-IV	Asia	Multi-center	Both	Both	No	Yes
				paroxetine	No	141	38.5 (1.6)	0.62	20-20	Fixed	20	HAMD 17	23.70								
Harris 1991	1991	2	2	fluvoxamine	Unclear	35	38.6 (12.1)	0.63	50-150	Flexible	115	HAMD 17	22.70	6	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				amitriptyline	Unclear	34	48.1 (12.3)	0.82	50-150	Flexible	99	HAMD 17	22.80								
Heiligenstein 1994	1994	2	2	fluoxetine	Yes	46	41.6 (10.9)	*	20-20	Fixed	20	HAMD 17	21.10	8	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes

				placebo	No	43	39.2 (9.8)	*	0-0	Fixed	0	HAMD 17	21.60							
Heller 2009 (NCT00909155)	2009	2	2	venlafaxine	Yes	15	30.74 (11.5)	0.53	75-300	Flexible	118	HAMD 21	20.07	24	DSM-IV	North America	Unclear	/Unclear	Other/Unclear	Unclear	Unclear
				fluoxetine	No	14	33.14 (10.7)	0.57	20-80	Flexible	37	HAMD 21	21.36							
Henigsberg 2012 (305, NCT00735709)	2012	3	4	placebo	No	140	46.4 (12.3)	0.61	0-0	Fixed	0	HAMD 24	32.70	8	DSM-IV	Cross-Continental	Multi-center	Unclear	Unclear	Unclear	Unclear
				vortioxetine	Yes	140	47.3 (11.9)	0.62	5-5	Fixed	5	HAMD 24	32.10							
				vortioxetine	Yes	140	46.4 (12.3)	0.61	10-10	Fixed	10	HAMD 24	33.10							
Heun 2013 (ISRCTI\l5750736O)	2013	2	2	agomelatine	Yes	151	71.9 (5.1)	0.70	25-50	Flexible	*	HAMD 17	26.80	8	DSM-IV	Cross-Continental	Multi-center	Both	Outpatients only	Unclear	Yes
				placebo	No	71	71.7 (4.8)	0.65	0-0	Flexible	0	HAMD 17	26.70							
Hewett 2009 (WXL101497)	2009	3	3	bupropion	Yes	188	41.8 (11.7)	*	150-300	Flexible	*	MADRS	30.40	12	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				venlafaxine	No	189	42.7 (11.48)	*	75-150	Flexible	*	MADRS	30.00							
				placebo	No	199	41.8 (11.6)	*	0-0	Flexible	0	MADRS	30.40							
Hewett 2010a (AK130940) (NCT00093288)	2010	2	2	bupropion	Yes	212	70.9 (5.55)	*	150-300	Flexible	*	MADRS	29.50	10	DSM-IV	Cross-Continental	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				placebo	No	208	71.3 (5.88)	*	0-0	Flexible	0	MADRS	29.80							
Hewett 2010b (AK130939)	2010	2	3	venlafaxine	No	198	44.1 (11.5)	*	75-150	Flexible	85	MADRS	30.10	8	DSM-IV	Cross-Continental	Multi-center	Unclear	Outpatients only	No	Unclear
				placebo	No	189	44.5 (10.8)	*	0-0	Flexible	0	MADRS	30.60							
Hicks 1988	1988	2	3	amitriptyline	No	16	42.2 (*)	*	25-300	Flexible	142	HAMD 17	30.8	6	DSM-III	North America	Single center	Secondary /Tertiary care	Inpatients only	Yes	Unclear
				placebo	No	15	40.8 (*)	*	0-0	Flexible	0	HAMD 17	29.4							
Hicks 2002	2002	2	2	nefazodone	Yes	20	42.8 (11.9)	0.40	400-600	Flexible	495	HAMD unspecified	21.60	24	DSM-IV	Europe	Single center	Secondary /Tertiary care	Outpatients only	Unclear	No
				paroxetine	No	20	43 (10.1)	0.45	20-40	Flexible	30	HAMD unspecified	22.30							
Higuchi 2014 (NCT01441440)	2016	3	3	venlafaxine	Yes	174	38.4 (11.9)	0.52	75-75	Fixed	75	HAMD 17	*	8	DSM-IV	Asia	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				venlafaxine	Yes	180	38.3 (10.2)	0.48	75-225	Flexible	*	HAMD 17	*							
				placebo	No	184	38.6 (11.1)	0.51	0-0	Flexible	0	HAMD 17	*							
Higuchi 2009	2009	4	4	duloxetine	Yes	75	37.9 (9.3)	*	40-40	Flexible	40	HAMD 17	20.60	6	DSM-IV	Asia	Multi-center	Both	Both	Yes	Yes
				duloxetine	Yes	75	39 (10.1)	*	60-60	Fixed	60	HAMD 17	20.40							
				paroxetine	No	148	37.9 (9.6)	*	20-40	Flexible	*	HAMD 17	20.40							

				placebo	No	146	38.7 (10.5)	*	0-0	Fixed	0	HAMD 17	20.40							
Higuchi 2011 (PCR112810, NCT00866294)	2011	3	3	paroxetine	Yes	83	35.5 (10.4)	*	20-40	Flexible	*	HAMD 17	22.70	8	DSM-IV	Asia	Multi-center	Unclear	Unclear	Yes	Unclear
				paroxetine	Yes	161	36.4 (11.5)	*	25-50	Flexible	*	HAMD 17	22.70								
				placebo	No	172	36.8 (10.1)	*	0-0	Flexible	0	HAMD 17	22.60								
Hirayasu 2011a	2011	3	3	escitalopram	Yes	105	35.9 (11.2)	*	20-20	Fixed	20	HAMD 17	22.20	8	DSM-IV	Asia	Multi-center	Both	Outpatients only	No	Yes
				escitalopram	Yes	100	33.1 (9)	*	10-10	Fixed	10	HAMD 17	22.30								
				placebo	No	105	34.7 (8.6)	*	0-0	Fixed	0	HAMD 17	22.50								
Hirayasu 2011b	2011	4	4	placebo	No	124	36.4 (10.8)	*	0-0	Fixed	0	MADRS	29.00	8	DSM-IV	Asia	Multi-center	Both	Outpatients only	Yes	Yes
				escitalopram	Yes	121	36.3 (9.7)	*	10-10	Fixed	10	MADRS	29.40								
				escitalopram	Yes	119	35.7 (9.8)	*	20-20	Fixed	20	MADRS	29.80								
				paroxetine	No	121	36.3 (8.4)	*	20-40	Flexible	*	MADRS	29.80								
Hong 2003 (22521)	2003	2	2	mirtazapine	Yes	66	47.2 (14.7)	*	30-45	Flexible	34	HAMD 17	23.10	6	DSM-IV	Asia	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				fluoxetine	No	66	47.1 (15.5)	*	20-40	Flexible	31	HAMD 17	24.30								
Hormazabal 1985	1985	2	3	amitriptyline	No	20	43.9 (15.3)	*	50-150	Flexible	86	HAMD 21	36.7	4	DSM-III	South America	Unclear	Unclear	Both	Unclear	Unclear
				placebo	No	20	42.3 (14.5)	*	0-0	Flexible	0	HAMD 21	35.8								
Hosseini 2015 (IRCT201203048513N1.)	2015	2	2	venlafaxine	No	28	37.12 (10.9)	0.75	37.5-150	Other/Unclear	*	HAMD unspecified	19.88	8	DSM-IV	Asia	Single center	Secondary /Tertiary care	Outpatients only	Unclear	Unclear
				citalopram	No	25	35.6 (8.72)	0.91	10-40	Other/Unclear	*	HAMD unspecified	17.63								
Hoyberg 1996 (Organon 88013, FDA88013)	1996	2	2	mirtazapine	Yes	56	70.3 (5.4)	*	15-45	Flexible	37	HAMD 17	26.70	6	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	No	Yes
				amitriptyline	No	59	71.3 (5.6)	*	30-90	Flexible	74	HAMD 17	25.70								
Hsu 2011	2011	2	2	citalopram	No	25	43.4 (11.4)	*	20-*	Flexible	23	MADRS	36.60	6	DSM-IV	Asia	Single center	Secondary /Tertiary care	Other/Unclear	No	Yes
				sertraline	No	26	38 (13.8)	*	50-*	Flexible	57	MADRS	38.20								
Hu 2009	2009	2	2	escitalopram	Unclear	25	30.92 (8.04)	0.52	10-20	Flexible	*	HAMD 17	21.30	6	Other operationalized	Asia	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				citalopram	Unclear	23	30.61 (8.61)	0.57	20-40	Flexible	*	HAMD 17	20.78								

Hunter 2010 (Study 1)	2010	2	2	fluoxetine	Yes	14	42.4 (12.6)	0.68	20-20	Fixed	20	HAMD 17	22.10	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	No
				placebo	No	14	42.4 (12.6)	0.68	0-0	Fixed	0	HAMD 17	22.10								
Hunter 2010 (Study 2)	2010	2	2	venlafaxine	Yes	17	44.7 (14)	0.64	150-150	Fixed	150	HAMD 17	22.30	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	No
				placebo	No	16	44.7 (14)	0.64	0-0	Fixed	0	HAMD 17	22.30								
Hunter 2010 (Study 3)	2010	2	2	venlafaxine	Yes	18	38.1 (12.5)	0.55	150-150	Fixed	150	HAMD 17	21.50	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Yes	No
				placebo	No	15	38.1 (12.5)	0.55	0-0	Fixed	0	HAMD 17	21.50								
Hutchinson 1992	1992	2	2	amitriptyline	No	32	71.5 (9.5)	*	100-100	Fixed	100	HAMD 21	20.28	6	DSM-III	Europe	Multi-center	Primary care	Outpatients only	Yes	Yes
				paroxetine	Yes	58	72 (5.6)	*	30-30	Fixed	30	HAMD 21	21.56								
Itil 1983	1983	2	3	fluvoxamine	Yes	22	41.3 (*)	0.43	50-300	Flexible	101	HAMD 17	20.30	4	RDC	North America	Unclear	Unclear	Outpatients only	Yes	Yes
				placebo	No	22	41.3 (*)	0.43	0-0	Flexible	0	HAMD 17	19.70								
Iwata 2013 (NCT00798707)	2013	2	3	desvenlafaxine	Yes	237	39 (12)	0.56	50-50	Fixed	50	HAMD 17	23	8	DSM-IV	Cross-Continental	Multi-center	Unclear	Outpatients only	Yes	Unclear
				placebo	No	235	40 (12)	0.55	0-0	Fixed	0	HAMD 17	23								
Jacobsen 2015 (316, NCT01163266)	2015	3	3	placebo	No	157	42.3 (11.6)	0.70	0-0	Fixed	0	MADRS	32.00	8	DSM-IV	North America	Multi-center	Unclear	Unclear	Unclear	Unclear
				vortioxetine	Yes	155	43.1 (12.0)	0.76	10-10	Fixed	10	MADRS	32.30								
				vortioxetine	Yes	150	43.1 (13.1)	0.71	20-20	Fixed	20	MADRS	32.40								
Jain 2013 (303, NCT00672958)	2013	2	2	placebo	No	300	42.4 (12.7)	0.55	0-0	Fixed	0	HAMD 24	32.20	6	DSM-IV	North America	Multi-center	Both	Outpatients only	Unclear	No
				vortioxetine	Yes	300	42.5 (13.0)	0.62	5-5	Fixed	5	HAMD 24	32.70								
Jefferson 2000 (29060/785)	2000	4	5	placebo	No	105	40.2 (11.5)	*	0-0	Fixed	0	MADRS	31.70	6	DSM-IV	North America	Multi-center	Unclear	Outpatients only	No	Unclear
				paroxetine	Yes	103	41.5 (12.1)	*	25-25	Fixed	25	MADRS	31.40								
				citalopram	Yes	107	38.4 (11.3)	*	20-20	Fixed	20	MADRS	31.40								
				citalopram	Yes	100	39.6 (11.1)	*	40-40	Fixed	40	MADRS	31.00								
Jefferson 2006	2006	2	2	placebo	No	139	39.8 (*)	*	0-0	Flexible	0	IDS-IVR-30	46.00	8	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				bupropion	Yes	135	40 (*)	*	300-450	Flexible	384	IDS-IVR-30	45.90								
Jiang 2009	2009	2	2	escitalopram	Unclear	32	38.62 (11.54)	0.56	10-20	Flexible	*	HAMD 17	23.82	6	Other operationalized	Asia	Single center	Secondary /Tertiary care	Both	Unclear	Yes
				citalopram	Unclear	32	39.23 (11.9)	0.53	20-60	Flexible	*	HAMD 17	23.46								

Judd 1993	1993	2	2	fluoxetine	Yes	30	41.7 (9.8)	0.66	20-20	Fixed	20	HAMD 17	24.40	6	DSM-III-R	Australia	Multi-center	Unclear	Unclear	Yes	Yes
				amitriptyline	No	28	41.7 (9.8)	0.66	150-200	Flexible	171	HAMD 17	23.70								
Kamijima 2013 (japicCTI-090733)	2013	3	3	milnacipran	Yes	303	35.9 (10.4)	0.53	100-100	Fixed	100	HAMD 17	22.10	9	DSM-IV	Asia	Multi-center	Unclear	Both	Yes	Yes
				milnacipran	Yes	301	36.7 (10.5)	0.51	200-200	Fixed	200	HAMD 17	22.30								
				paroxetine	No	301	36.6 (11.1)	0.55	30-40	Flexible	*	HAMD 17	22.10								
Kane 1983	1983	2	4	bupropion	Unclear	13	63.9 (6.98)	*	100-450	Flexible	323	HAMD unspecified	24.10	4	Other operationalized	North America	Multi-center	Unclear	Unclear	Yes	Unclear
				placebo	No	7	63.9 (6.98)	*	0-0	Flexible	0	HAMD unspecified	25.60								
Kasper 2005a (Study 99024)	2005	3	3	escitalopram	Yes	174	75 (7)	*	10-10	Fixed	10	MADRS	28.20	8	DSM-IV	Europe	Multi-center	Both	Both	Yes	Unclear
				fluoxetine	No	164	75 (7)	*	20-20	Fixed	20	MADRS	28.50								
				placebo	No	180	75 (7)	*	0-0	Fixed	0	MADRS	28.60								
Kasper 2005b	2005	2	2	paroxetine	Unclear	53	44.3 (11.3)	0.68	20-40	Flexible	22	HAMD 17	20.90	6	DSM-IV	Europe	Multi-center	Unclear	Outpatients only	Yes	Yes
				trazodone	Unclear	55	43.5 (12.2)	0.58	150-450	Flexible	305	HAMD 17	21.00								
Kasper 2012 (NCT00807248)	2012	2	4	escitalopram	Yes	140	41.6 (12.6)	0.69	20-20	Fixed	20	MADRS	35.40	8	DSM-IV	Europe	Multi-center	Secondary /Tertiary care	Both	Unclear	No
				placebo	No	71	42.6 (11.6)	0.75	0-0	Fixed	0	MADRS	34.70								
Katona 2012 (12541A, NCT00811252)	2012	3	3	placebo	No	145	70.3 (4.4)	0.62	0-0	Fixed	0	HAMD 24	29.40	8	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	Unclear	Unclear
				vortioxetine	Yes	156	70.5 (4.8)	0.69	5-5	Fixed	5	HAMD 24	29.20								
				duloxetine	No	151	70.9 (5.5)	0.66	60-60	Fixed	60	HAMD 24	28.50								
Katz 1993a	1993	2	3	amitriptyline	No	95	42.6 (*)	*	75-150	Flexible	*	HAMD 17	24.3	4	DSM-III	Cross-Continental	Unclear	Unclear	Unclear	Yes	Yes
				placebo	No	94	44.7 (*)	*	0-0	Flexible	0	HAMD 17	24.5								
Katz 1993b	1993	2	3	amitriptyline	No	93	43.2 (*)	*	75-225	Flexible	*	HAMD 17	23.6	4	DSM-III-R	Cross-Continental	Unclear	Unclear	Unclear	Yes	Yes
				placebo	No	104	44 (*)	*	0-0	Flexible	0	HAMD 17	22.2								
Katz 2004	2004	2	3	paroxetine	Unclear	28	46 (*)	*	20-60	Flexible	*	HAMD 21	24.00	6	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Unclear
				placebo	No	25	46 (*)	*	0-0	Flexible	0	HAMD 21	25.90								
Kavoussi 1997	1997	2	2	bupropion	Yes	122	39.2 (10.3)	0.48	100-300	Flexible	238	HAMD unspecified	*	16	DSM-IV	North America	Multi-center	Unclear	Outpatients only	No	Yes
				sertraline	No	126	40 (10.5)	0.48	50-200	Flexible	114	HAMD unspecified	*								

Keegan 1991	1991	2	2	fluoxetine	Yes	20	39.5 (13.6)	0.67	20-80	Flexible	53	HAMD 21	*	6	DSM-III	North America	Multi-center	Unclear	Unclear	Yes	Yes
				amitriptyline	No	22	47.8 (14.2)	0.67	100-250	Flexible	171	HAMD 21	*								
Kellams 1979	1979	2	3	trazodone	Unclear	9	*	*	200-600	Flexible	515	HAMD unspecified	23.50	4	Other operationalized	North America	Single center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				placebo	No	9	*	*	0-0	Flexible	0	HAMD unspecified	26.90								
Keller 2006a (Study 059, NCT00035009)	2006	2	3	paroxetine	No	154	39 (*)	0.68	20-20	Fixed	20	HAMD 17	27.50	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				placebo	No	155	41.4 (*)	0.61	0-0	Fixed	0	HAMD 17	27.70								
Keller 2006b (Study 061) (NCT00035295)	2006	2	4	paroxetine	No	143	42.2 (*)	0.75	20-20	Fixed	20	HAMD 17	27.60	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				placebo	No	145	41.1 (*)	0.74	0-0	Fixed	0	HAMD 17	27.30								
Keller 2006c (Study 062) (NCT00048607)	2006	2	4	paroxetine	No	164	40.6 (*)	0.64	20-20	Fixed	20	HAMD 17	28.30	8	DSM-IV	Cross-Continental	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				placebo	No	161	41.3 (*)	0.71	0-0	Fixed	0	HAMD 17	28.30								
Keller 2007 (NCT00046020)	2007	2	2	fluoxetine	Unclear	275	40 (11.6)	*	20-60	Flexible	50	HAMD 17	23.00	10	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	No
				venlafaxine	Yes	821	39.6 (11.2)	*	75-300	Flexible	208	HAMD 17	22.60								
Kennedy 2005 (SCT-MD-16)	unpublished	2	2	escitalopram	Yes	102	37.1 (11.4)	*	10-20	Flexible	*	HAMD unspecified	25.90	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	No	103	37 (11.8)	*	20-40	Flexible	*	HAMD unspecified	26.50								
Kennedy 2008 (CL3-20098-043)	2003	2	2	agomelatine	Yes	107	42.3 (12.7)	0.65	25-50	Flexible	*	HAMD 17	26.50	6	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	No	No
				placebo	No	105	42.7 (12)	0.55	0-0	Flexible	0	HAMD 17	26.70								
Kennedy 2014 (EudraCT 2009-011238-84, CL3-20098-069)	2014	3	4	agomelatine	Yes	138	46.5 (11.9)	0.65	25-25	Fixed	25	HAMD 17	26.70	6	DSM-IV	Cross-Continental	Multi-center	Unclear	Outpatients only	Unclear	No
				agomelatine	Yes	137	43.1 (12.6)	0.72	25-50	Flexible	*	HAMD 17	26.70								
				placebo	No	141	45 (13.1)	0.77	0-0	Flexible	0	HAMD 17	26.60								
Kerkhofs 1990	1990	2	2	fluoxetine	Yes	16	45.3 (12.7)	0.69	60-60	Fixed	60	HAMD unspecified	21.90	6	RDC	Europe	Unclear	Unclear	Other/Unclear	Yes	Yes
				amitriptyline	No	18	46.2 (11.4)	0.61	150-150	Fixed	150	HAMD unspecified	21.80								
Kerr 1984	1984	2	2	amitriptyline	No	38	62.5(median) (*)	0.62	75-225	Flexible	*	HAMD 17	19.00	6	Other operationalized	Europe	Multi-center	Secondary /Tertiary care	Both	Unclear	Unclear
				trazodone	Yes	36	59 (median) (*)	0.76	150-300	Flexible	*	HAMD 17	20.00								
Khan 1998	1998	4	4	venlafaxine	Yes	85	43.3 (*)	0.68	75-75	Fixed	75	HAMD 21	24.30	12	DSM-III-R	North America	Multi-center	Unclear	Outpatients only	yes	unclear

				venlafaxine	Yes	90	40 (*)	0.64	150-150	Fixed	150	HAMD 21	24.50							
				venlafaxine	Yes	83	43.6 (*)	0.60	200-200	Fixed	200	HAMD 21	24.80							
				placebo	No	95	40.2 (*)	0.61	0-0	Fixed	0	HAMD 21	25.10							
Khan 2007 (SCT-MD-23, NCT00108979)	2007	2	2	escitalopram	Yes	140	41.8 (12.7)	*	10-20	Flexible	*	HAMD 24	26.60	8	DSM-IV	North America	Multi-center	Unclear	Outpatients only	Unclear	Unclear
				duloxetine	No	138	43 (13.4)	*	60-60	Fixed	60	HAMD 24	26.90							
Khan 2011 (CLDA-07-DP-02, NCT00683592)	2011	2	2	vilazodone	Yes	240	41.1 (12.2)	*	40-40	Fixed	40	HAMD 17	25.00	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				placebo	No	241	42.4 (12.5)	*	0-0	Fixed	0	HAMD 17	25.30							
Kiev 1997	1997	2	2	fluvoxamine	Yes	30	42.7 (*)	*	50-150	Flexible	102	HAMD 21	24.40	7	DSM-III-R	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Yes	Yes
				paroxetine	No	30	39.9 (*)	*	20-50	Flexible	36	HAMD 21	24.40							
Kinoshita 2009	2009	4	4	mirtazapine	Yes	70	39.4 (10.9)	*	15-15	Fixed	15	HAMD 17	23.20	6	DSM-IV	Asia	Multi-center	Both	Both	No	No
				mirtazapine	Yes	70	37.7 (10.8)	*	30-30	Fixed	30	HAMD 17	22.50							
				mirtazapine	Yes	71	41.6 (12.5)	*	45-45	Fixed	45	HAMD 17	22.10							
				placebo	No	70	39.9 (12.8)	*	0-0	Fixed	0	HAMD 17	22.50							
Koshino 2013 (NCT01138007)	2013	2	3	bupropion	Yes	192	37.5 (10.9)	0.56	300-300	Fixed	300	MADRS	32.10	8	DSM-IV	Asia	Multi-center	Secondary/Tertiary care	Other/Unclear	Unclear	Unclear
				placebo	No	187	37.9 (11.1)	0.54	0-0	Fixed	0	MADRS	31.90							
Kramer 1998	1998	2	3	paroxetine	Unclear	72	*	*	20-20	Fixed	20	HAMD 21	*	6	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				placebo	No	70	*	*	0-0	Fixed	0	HAMD 24	*							
Kuhs 1989 (MDUK_29060_III_85_043)	1989	2	2	paroxetine	Yes	12	39.2 (11.8)	0.9	30-30	Fixed	30	HAMD 21	24.60	6	DSM-III	Europe	Single center	Other/Unclear	Other/Unclear	Yes	Unclear
				amitriptyline	No	12	39.1 (11.5)	1.0	150-150	Fixed	150	HAMD 21	25.00							
Kusalic 1993	1993	2	3	amitriptyline	No	13	41.3 (10.1)	*	*-*	Flexible	110	HAMD 17	*	6	DSM-III-R	North America	Unclear	Secondary/Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	15	41.3 (10.1)	*	0-0	Flexible	0	HAMD 17	*							
Kyle 1998 (Study 92032 - FDA)	1998	2	2	citalopram	Yes	179	73.4 (*)	0.73	20-40	Flexible	24	MADRS	27.8	8	DSM-III-R	Europe	Multi-center	Primary care	Other/Unclear	Yes	Unclear
				amitriptyline	No	186	74.1 (*)	0.74	50-100	Flexible	57	MADRS	29.4							
Laakman 1988	1988	2	2	fluoxetine	Unclear	63	*	*	20-60	Flexible	*	HAMD unspecified	26.7	5	Other operationalized	Europe	Unclear	Other/Unclear	Outpatients only	Yes	Yes

				amitriptyline	Unclear	65	*	*	50-150	Flexible	*	HAMD unspecified	23.8							
Lalit 2004	2004	3	3	escitalopram	Yes	69	33 (8)	*	10-20	Flexible	*	HAMD 17	26.00	4	ICD-10	Asia	Multi-center	Other/Unclear	Outpatients only	No	Yes
				citalopram	Yes	74	33 (9)	*	20-40	Flexible	*	HAMD 17	25.00							
				sertraline	No	71	37 (11)	*	100-150	Flexible	*	HAMD 17	25.00							
Lam 1995	1995	2	2	fluoxetine	Yes	36	40.9 (8.6)	*	20-20	Fixed	20	HAMD 21	18.70	5	DSM-III-R	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Yes	No
				placebo	No	32	38.1 (9.7)	*	0-0	Fixed	0	HAMD 21	18.30							
Langlois 1985	1985	2	3	amitriptyline	No	15	*	*	150-225	Flexible	*	HAMD 17	*	4	DSM-III	North America	Single center	Secondary/Tertiary care	Outpatients only	No	Unclear
				placebo	No	15	*	*	0-0	Flexible	0	HAMD 17	*							
Lapierre 1980	1980	2	2	amitriptyline	Unclear	20	*	*	150-150	Fixed	150	*	*	4	Feighner	North America	Unclear	Secondary/Tertiary care	Both	Yes	Unclear
				trazodone	Unclear	20	*	*	150-150	Fixed	150	*	*							
Lapierre 1987	1987	2	3	fluvoxamine	Yes	22	43.3 (*)	*	150-300	Flexible	207	HAMD 17	24.84	6	DSM-III	North America	Multi-center	Secondary/Tertiary care	Inpatients only	Yes	Unclear
				placebo	No	20	45.8 (*)	*	0-0	Flexible	0	HAMD 17	21.98							
Larsen 1989	1989	2	3	clomipramine	Unclear	20	48 (*)	0.65	75-150	Fixed	150	HAMD 17	17.80	6	DSM-III	Europe	Unclear	Other/Unclear	Both	Unclear	Yes
				placebo	No	18	57 (*)	0.67	0-0	Fixed	0	HAMD 17	18.30							
Learned 2012a Study1 (EUCTR2005-003401-87, SND103285, NCT00448058)	2012	2	3	venlafaxine	No	134	43 (11.19)	0.61	150-225	Flexible	*	HAMD 17	*	10	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				Placebo	No	126	41.9 (11.8)	0.64	0-0	Flexible	0	HAMD 17	*							
Learned 2012b Study2 (NCT00420641)	2012	2	3	paroxetine	Yes	166	44.4 (10.9)	0.33	30-30	Fixed	30	MADRS	30.30	10	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				placebo	No	156	41.8 (10.9)	0.25	0-0	Fixed	0	MADRS	31.80							
Lecrubier 1997	1997	2	3	venlafaxine	Unclear	78	38.3 (*)	0.71	75-150	Flexible	128	MADRS	24.90	13	RDC	Europe	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				placebo	No	76	40.5 (*)	0.63	0-0	Flexible	0	MADRS	24.20							
Lee 2007 (F1J-AA-HMCV) (NCT00489775)	2007	2	2	duloxetine	Yes	238	39 (13.9)	*	60-60	Fixed	60	HAMD 17	21.10	8	DSM-IV	*	Multi-center	Secondary/Tertiary care	Both	No	Unclear
				paroxetine	No	240	38 (15.3)	*	20-20	Fixed	20	HAMD 17	21.20							
Leinonen 1997	1997	2	2	milnacipran	Yes	52	49.2 (9.8)	*	100-200	Flexible	*	HAMD 17	23.70	26	DSM-III-R	Europe	Multi-center	Secondary/Tertiary care	Both	Unclear	Yes
				clomipramine	No	55	47.1 (10.6)	*	75-150	Flexible	*	HAMD 17	23.10							

Leinonen 1999 (Agren1995)	1999	2	2	mirtazapine	Yes	137	42.1 (12.3)	*	15-60	Flexible	35	MADRS	29.60	8	DSM-IV	Europe	Multi-center	Secondary /Tertiary care	Both	Yes	Yes
				citalopram	No	133	41.1 (10.8)	*	20-60	Flexible	37	MADRS	29.10								
Lemoine 2007 (CL3-20098-035)	2004	2	4	agomelatine	Yes	165	40.7 (10.7)	0.75	25-50	Fixed	50	HAMD 17	25.90	24	DSM-IV	Europe	Multi-center	Primary care	Outpatients only	No	No
				venlafaxine	No	167	39.6 (10.3)	0.67	75-150	Fixed	150	HAMD 17	26.00								
Lepine 2000	2000	2	2	sertraline	Yes	82	42.3 (*)	0.71	50-200	Flexible	114	HAMD 17	29.8	8	DSM-III-R	Cross-Continental	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				clomipramine	No	84	41.8 (*)	0.69	50-150	Flexible	98	HAMD 17	29.6								
Lepola 2003 (ESC 99003)	2001	3	3	escitalopram	Yes	156	43 (11)	*	10-20	Flexible	*	MADRS	29.00	8	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	Yes	Unclear
				citalopram	No	161	44 (11)	*	20-40	Flexible	*	MADRS	29.20								
				placebo	No	154	43 (12)	*	0-0	Flexible	0	MADRS	28.70								
Li 2006	2006	2	2	escitalopram	Unclear	28	36.5 (12.8)	0.55	10-20	Flexible	*	HAMD 17	23.70	6	Other operationalized	Asia	Single center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				citalopram	Unclear	28	34.4 (11.9)	0.53	20-40	Flexible	*	HAMD 17	23.80								
Li 2010	2010	2	2	escitalopram	Yes	24	*	*	10-20	Flexible	*	HAMD unspecified	*	6	Other operationalized	Asia	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				citalopram	Yes	24	*	*	20-40	Flexible	*	HAMD unspecified	*								
Lieberman 2008a (Study 309, EUCTR2004-000562-13, 3151A1-309-EU, NCT00090649)	2008	2	3	placebo	No	120	45.4 (12)	0.67	0-0	Flexible	0	HAMD 17	*	8	DSM-IV	Europe	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				venlafaxine	Yes	127	45.9 (12)	0.72	75-150	Flexible	*	HAMD 17	25.8								
Lieberman 2008b (Study 317)	2008	2	3	placebo	No	125	39.5 (11.4)	0.64	0-0	Flexible	0	HAMD 17	*	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				venlafaxine	Yes	117	41.5 (11.6)	0.70	150-225	Flexible	*	HAMD 17	25.1								
Liebowitz 2008 (Study 332, NCT00277823)	2008	3	3	desvenlafaxine	Yes	151	43 (15)	0.62	50-50	Fixed	50	HAMD 17	23.37	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Yes
				desvenlafaxine	Yes	148	43 (13)	0.53	100-100	Fixed	100	HAMD 17	23.35								
				placebo	No	152	42 (14)	0.63	0-0	Fixed	0	HAMD 17	23.02								
Liebowitz 2013 (NCT00863798)	2013	2	3	desvenlafaxine	Yes	227	43 (14)	0.60	50-50	Fixed	50	HAMD 17	23	8	DSM-IV	North America	Multi-center	Both	Outpatients only	Yes	Unclear

				placebo	No	227	42 (13)	0.62	0-0	Fixed	0	HAMD 17	23							
Lineberry 1990 (WELL 84A)	1990	2	2	bupropion	Yes	112	41.9 (*)	*	300-300	Fixed	300	HAMD 21	26.54	6	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	112	40.8 (*)	*	0-0	Fixed	0	HAMD 21	27.02							
Loo 2002 (CL2-014)	2002	3	5	agomelatine	Yes	137	42.3 (*)	0.67	25-25	Fixed	25	HAMD 17	27.40	8	DSM-IV	Europe	Multi-center	Both	Other/Unclear	Yes	Yes
				placebo	No	139	42.3 (*)	0.67	0-0	Fixed	0	HAMD 17	27.40							
				paroxetine	No	147	42.3 (*)	0.67	20-20	Fixed	20	HAMD 17	27.30							
LopezRodriguez 2004	2004	2	4	fluoxetine	Unclear	10	31.9 (*)	*	20-20	Fixed	20	HAMD 21	17.27	20	DSM-IV	South America	Single center	Primary care	Outpatients only	No	Unclear
				placebo	No	10	31.9 (*)	*	0-0	Fixed	0	HAMD 21	17.27							
Lv 2013	2013	2	2	escitalopram	Unclear	20	32.1 (7.64)	0.50	10-20	Flexible	*	HAMD 17	23.06	6	Other operationalized	Asia	Single center	Secondary /Tertiary care	Outpatients only	Unclear	Yes
				citalopram	Unclear	22	31.61 (8.61)	0.50	20-40	Flexible	*	HAMD 17	22.78							
Lydiard 1989	1989	2	3	fluvoxamine	Yes	18	47.2 (*)	*	100-300	Flexible	240	HAMD unspecified	24.50	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	18	47.2 (*)	*	0-0	Flexible	0	HAMD unspecified	26.00							
Lydiard 1997	1997	3	3	amitriptyline	No	131	39 (*)	*	50-150	Flexible	103	HAMD 17	22.1	8	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				placebo	No	129	40.2 (*)	*	0-0	Flexible	0	HAMD 17	22.1							
				sertraline	No	132	41.2 (*)	*	50-200	Flexible	139	HAMD 17	21.5							
M/2020/0046 (Study 046)	unpublished	3	3	reboxetine	Yes	265	39.9 (11.1)	0.71	8-10	Flexible	9	HAMD 21	23.00	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	No	Yes
				placebo	No	257	39 (11.6)	0.70	0-0	Flexible	0	HAMD 21	23.00							
				paroxetine	No	265	39.8 (11.8)	0.69	20-40	Flexible	29	HAMD 21	22.80							
M/2020/0047 (Study 047)	unpublished	3	3	reboxetine	Yes	258	39.3 (11.6)	0.74	8-10	Flexible	9	HAMD 21	24.20	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	No	Yes
				placebo	No	254	37.1 (11)	0.82	0-0	Flexible	0	HAMD 21	23.70							
				paroxetine	No	262	39.8 (10.8)	0.72	20-40	Flexible	33	HAMD 21	23.90							
Mahableshwarkar 2013 (304, NCT00672620)	2013	3	4	placebo	No	153	42.6 (13.7)	0.61	0-0	Fixed	0	HAMD 24	29.50	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				vortioxetine	Yes	153	43.1 (13.9)	0.69	5-5	Fixed	5	HAMD 24	29.80							
				duloxetine	No	152	42.7 (14.4)	0.60	60-60	Fixed	60	HAMD 24	28.70							
	2015	4	4	placebo	No	161	42.4 (12.6)	0.72	0-0	Fixed	0	MADRS	31.60	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	No

Mahableshwarkar 2015a (315, NCT01153009)				vortioxetine	Yes	147	43.1 (12.3)	0.71	15-15	Fixed	15	MADRS	31.90							
				vortioxetine	Yes	154	42.8 (12.4)	0.74	20-20	Fixed	20	MADRS	32.00							
				duloxetine	No	152	43.4 (12.2)	0.78	60-60	Fixed	60	MADRS	32.90							
Mahableshwarkar 2015b (317, NCT01179516)	2015	3	3	placebo	No	160	46.2 (11.8)	0.68	0-0	Fixed	0	MADRS	33.40	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				vortioxetine	Yes	157	45.2 (11.9)	0.72	10-10	Fixed	10	MADRS	34.10							
				vortioxetine	Yes	152	43.8 (13.5)	0.71	15-15	Fixed	15	MADRS	33.70							
Mahableshwarkar 2015c (NCT01564862)	2015	3	3	vortioxetine	Yes	198	44.2 (12.2)	0.68	10-20	Flexible	16	MADRS	31.40	8	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	Unclear	Unclear
				duloxetine	No	210	45.7 (11.5)	0.66	60-60	Fixed	60	MADRS	31.70							
				placebo	No	194	45 (12.1)	0.61	0-0	Fixed	0	MADRS	31.90							
Mann 1981	1981	2	3	trazodone	Yes	10	44.5 (3.9)	0.10	200-600	Flexible	418	HAMD unspecified	26.30	4	Feighner	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	10	47.2 (4.1)	0.11	0-0	Flexible	0	HAMD unspecified	22.90							
Manna 1989	1989	2	2	fluoxetine	Unclear	15	47.7 (10)	0.63	20-20	Fixed	20	HAMD 17	25.7	5	DSM-III	Europe	Unclear	Secondary /Tertiary care	Inpatients only	Unclear	Unclear
				clomipramine	Unclear	15	48.5 (8.36)	0.63	75-75	Fixed	75	HAMD 17	25							
Mao 2008	2008	2	2	fluoxetine	No	117	40.7 (13.9)	0.74	20-20	Fixed	20	HAMD 17	24.10	8	DSM-IV	Asia	Multi-center	Secondary /Tertiary care	Both	No	Yes
				escitalopram	Yes	123	37.1 (14.1)	0.61	10-10	Fixed	10	HAMD 17	24.70							
Mao 2015 (NCT01098318)	2015	2	3	sertraline	No	19	41.4 (14.6)	0.53	50-200	Flexible	*	HAMD 17	15.40	12	DSM-IV	North America	Single center	Primary care	Outpatients only	Unclear	Unclear
				placebo	No	18	46.7 (15.2)	0.44	0-0	Fixed	0	HAMD 17	14.40							
March 1990	1990	2	3	fluvoxamine	Yes	18	39.4 (*)	*	100-300	Flexible	*	HAMD unspecified	25.10	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	18	39.4 (*)	*	0-0	Flexible	0	HAMD unspecified	27.30							
Marchesi 1998	1998	2	2	fluoxetine	Yes	67	43.6 (11.9)	0.73	20-20	Fixed	20	HAMD 17	25.50	10	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				amitriptyline	No	75	43.6 (11.9)	0.75	75-225	Flexible	115	HAMD 17	25.30							
Masco 1985	1985	2	2	fluoxetine	Yes	21	51 (*)	0.65	40-80	Flexible	*	HAMD unspecified	*	6	*	North America	Unclear	Secondary /Tertiary care	Outpatients only	Unclear	Unclear
				amitriptyline	No	21	51 (*)	0.81	150-300	Flexible	*	HAMD unspecified	*							
Mathews 2015 (NCT01473381)	2015	4	4	vilazodone	Yes	292	41.7 (12.7)	0.58	20-20	Fixed	17	MADRS	31.00	10	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Yes

				vilazodone	Yes	291	40.8 (13.2)	0.57	40-40	Fixed	30	MADRS	30.80							
				placebo	No	290	42 (13)	0.56	0-0	Fixed	0	MADRS	31.30							
				citalopram	No	289	42.6 (12.6)	0.59	40-40	Fixed	40	MADRS	31.10							
McGrath 2000	2000	2	2	fluoxetine	Yes	49	41.6 (11)	*	20-60	Flexible	51	HAMD 17	*	10	DSM-IV	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	52	41.6 (11)	*	0-0	Flexible	0	HAMD 17	*							
McIntyre 2014 (NCT01422213)	2014	3	3	placebo	No	198	45.6 (12.1)	0.66	0-0	Fixed	0	MADRS	31.34	8	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	Unclear	No
				vortioxetine	Yes	197	45.4 (12.2)	0.69	10-10	Fixed	10	MADRS	31.62							
				vortioxetine	Yes	207	46.1 (11.8)	0.64	20-20	Fixed	20	MADRS	31.74							
McPartlin 1998	1998	2	2	paroxetine	No	178	44 (14)	*	20-20	Fixed	20	HAMD 17	23.00	12	DSM-IV	Europe	Multi-center	Primary care	Outpatients only	Unclear	Yes
				venlafaxine	Yes	183	45 (15)	*	75-75	Fixed	75	HAMD 17	23.00							
MDF/29060/III/070/88/MC	unpublished	2	2	paroxetine	Yes	32	73 (*)		20-30	Flexible	*	MADRS	30.88	5	Feighner	Europe	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				clomipramine	No	30	73 (*)		60-75	Flexible	*	MADRS	29.00							
MDUK/26090/III/83/007	unpublished	2	3	paroxetine	Yes	4	*	0.50	15-30	Flexible	*	*	*	4	Feighner	Europe	Single center	Secondary /Tertiary care	Inpatients only	Unclear	Unclear
				placebo	No	3	*	0.67	0-0	Flexible	0	*	*							
Mehtonen 2000	2000	2	2	sertraline	No	72	41 (10.7)	*	50-100	Flexible	*	HAMD 21	25.80	8	DSM-IV	Europe	Multi-center	Other/Unclear	Outpatients only	No	Unclear
				venlafaxine	Yes	75	44.1 (11.4)	*	75-150	Flexible	*	HAMD 21	25.50							
Mendels 1995 (FDA 03A0A-004B)	1995	3	3	nefazodone	Yes	80	38.4 (*)	0.64	50-300	Flexible	247	HAMD 17	25.10	6	DSM-III	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				nefazodone	Yes	80	39.1 (*)	0.60	100-600	Flexible	397	HAMD 17	25.40							
				placebo	No	80	40.1 (*)	0.61	0-0	Flexible	0	HAMD 17	25.00							
Mendels 1999 (Study 85A - FDA)	1999	2	2	citalopram	No	89	43.3 (*)	*	20-80	Flexible	52	HAMD 24	33.52	4	DSM-III	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	91	42.7 (*)	*	0-0	Flexible	0	HAMD 24	33.72							
Miller 1989 (MDUK/29060/III/82/006 (PAR-274) PAR UK 06 - FDA)	1989	2	2	paroxetine	Yes	22	41.6 (13.2)	*	30-30	Fixed	30	HAMD 21	23.70	4	Feighner	Europe	Single center	Other/Unclear	Outpatients only	Unclear	Unclear
				placebo	No	25	43.3 (11.8)	*	0-0	Fixed	0	HAMD 21	24.20							
MIR 003-003 (FDA)	unpublished	2	2	mirtazapine	Yes	45	43 (*)	0.47	*-35	Flexible	27	HAMD 21	25.40	6	*	North America	Unclear	Other/Unclear	Other/Unclear	Yes	Yes
				placebo	No	45	43 (*)	0.67	0-0	Flexible	0	HAMD 21	25.50							

MIR 003-020 (FDA)	unpublished	3	3	mirtazapine	Yes	44	44 (*)	0.46	5-35	Flexible	24	HAMD 21	27.80	6	*	North America	Unclear	Other/Unclear	Outpatients only	Yes	Yes
				amitriptyline	No	43	43 (*)	0.45	40-280	Flexible	137	HAMD 21	29.20								
				placebo	No	43	45 (*)	0.62	0-0	Flexible	0	HAMD 21	29.50								
MIR 003-021 (FDA)	unpublished	3	3	mirtazapine	Yes	50	45 (*)	0.56	5-35	Flexible	21	HAMD 21	24.20	6	*	North America	Unclear	Other/Unclear	Outpatients only	Yes	Yes
				amitriptyline	No	50	44 (*)	0.54	40-280	Flexible	116	HAMD 21	25.00								
				placebo	No	50	48 (*)	0.56	0-0	Flexible	0	HAMD 21	24.40								
MIR 84062 (FDA)	unpublished	3	3	mirtazapine	Yes	15	*	*	*	Flexible	*	HAMD 17	*	6	DSM-III	Europe	Single center	Other/Unclear	Outpatients only	Unclear	Unclear
				amitriptyline	No	15	*	*	*	Flexible	*	HAMD 17	*								
				placebo	No	15	*	*	0-0	Flexible	0	HAMD 17	*								
Mischoulon 2014 (NCT00101452)	2014	2	3	escitalopram	No	69	45 (15)	0.50	10-20	Flexible	*	HAMD 17	19.25	12	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				placebo	No	65	45 (15)	0.50	*	Flexible	*	HAMD 17	19.43								
Miura 2000	2000	2	2	paroxetine	Yes	109	45.9 (13.9)	*	20-40	Flexible	32	HAMD 17	23.80	6	DSM-IV	Asia	Multi-center	Secondary /Tertiary care	Both	No	Yes
				amitriptyline	No	119	47.1 (13.8)	*	50-150	Flexible	109	HAMD 17	23.90								
Moises 1981	1981	2	2	amitriptyline	Unclear	22	48.7 (*)	0.86	150-200	Flexible	164	HAMD unspecified	24.9	4	Other operationalized	Europe	Single center	Secondary /Tertiary care	Inpatients only	Unclear	Yes
				trazodone	Unclear	21	48.7 (*)	0.86	450-600	Flexible	512	HAMD unspecified	25.3								
Moller 1993 (Stuppaeck 1994, MY-059.073/29060/1)	1993	2	2	paroxetine	Yes	78	47.5 (11.6)	*	30-50	Flexible	33	HAMD 21	28.60	6	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				amitriptyline	No	75	46.6 (11.4)	*	150-250	Flexible	166	HAMD 21	28.90								
Moller 1998 (Hegerl 1997)	1998	2	2	amitriptyline	No	79	49.5 (12.9)	0.71	75-225	Flexible	141	HAMD 21	29.1	6	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	No	Yes
				sertraline	Yes	81	47.7 (13)	0.69	50-150	Flexible	105	HAMD 21	28.3								
Moller 2000	2000	2	2	sertraline	Yes	116	47.7 (13.2)	*	50-100	Flexible	55	HAMD 21	27.10	6	DSM-III-R	Europe	Multi-center	Both	Outpatients only	No	Yes
				amitriptyline	No	124	48.1 (14)	*	75-150	Flexible	87	HAMD 21	27.50								
Montgomery 1992 (Study 89303 FDA)	unpublished	3	3	citalopram	Yes	70	*	*	20-20	Fixed	20	HAMD 17	24.29	6	DSM-III-R	*	Multi-center	Other/Unclear	Both	Yes	Yes
				citalopram	Yes	64	*	*	40-40	Fixed	40	HAMD 17	22.98								
				placebo	No	66	*	*	0-0	Fixed	0	HAMD 17	23.72								
Montgomery 2004a (Study 99067)	2004	2	2	escitalopram	Yes	148	49 (15)	*	10-20	Flexible	12	HAMD 17	19.99	8	DSM-IV	Europe	Multi-center	Primary care	Other/Unclear	No	Unclear
				venlafaxine	No	145	47 (14)	*	75-150	Flexible	95	HAMD 17	20.44								

Montgomery 2004b (CL3-20098-030)	2001	2	2	agomelatine	Yes	167	42.8 (13.5)	*	25-25	Fixed	25	MADRS	23.10	12	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	No
				paroxetine	No	168	42.1 (13.4)	*	20-20	Fixed	20	MADRS	23.00								
Montgomery 2013 (F02695LP202, EudraCT2006-002404-34)	2013	2	2	placebo	No	281	45 (*)	0.66	0-0	Flexible	0	HAMD 17	25.80	10	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Outpatients only	Unclear	Yes
				levomilnacipran	Yes	282	44 (*)	0.67	75-100	Flexible	65	HAMD 17	26.20								
Moon 1994	1994	2	2	sertraline	Yes	51	42 (*)	0.41	50-150	Flexible	64	HAMD 17	23.9	6	DSM-III	Europe	Multi-center	Primary care	Outpatients only	Yes	Yes
				clomipramine	No	55	45 (*)	0.60	50-150	Flexible	61	HAMD 17	22.7								
Moore 2005	2005	2	2	escitalopram	Yes	142	44.1 (10.9)	*	20-20	Fixed	20	MADRS	36.30	8	DSM-IV	Europe	Multi-center	Both	Outpatients only	No	Unclear
				citalopram	No	152	46.2 (11.1)	*	40-40	Fixed	40	MADRS	35.70								
Moreno 2005	2005	2	3	fluoxetine	No	20	37.7 (9.9)	0.83	20-20	Fixed	20	HAMD 21	15.41	8	DSM-IV	South America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	26	45.9 (10.8)	0.83	0-0	Fixed	0	HAMD 21	16.49								
Moscovitch 2004	2004	2	2	sertraline	Yes	93	39.6 (11.6)	*	50-200	Flexible	111	HAMD 17	18.62	8	DSM-III-R	Cross-Continental	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	94	40 (11.2)	*	0-0	Flexible	0	HAMD 17	17.76								
Mullin 1996	1996	2	2	mirtazapine	Yes	79	45.4 (11.8)	*	20-60	Flexible	*	HAMD 17	22.50	5	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				amitriptyline	No	77	44.2 (10.3)	*	75-225	Flexible	*	HAMD 17	22.60								
Mundt 2012 (NCT00406952)	2012	2	2	sertraline	Yes	80	37.8 (12.5)	0.63	50-100	Flexible	*	HAMD 17	24.90	4	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				placebo	No	85	37.8 (12.5)	0.63	0-0	Flexible	0	HAMD 17	24.60								
Munizza 2006	2006	2	2	sertraline	No	60	46.9 (10.6)	0.70	50-100	Flexible	59	HAMD 17	21.9	6	DSM-IV	Europe	Multi-center	Other/Unclear	Outpatients only	Unclear	Yes
				trazodone	Yes	62	45 (11.5)	0.60	150-450	Flexible	297	HAMD 17	21.7								
Murasaki 1998	1998	2	2	fluvoxamine	Yes	113	40.5 (*)	*	50-150	Flexible	87	HAMD 21	22.90	4	DSM-III-R	Asia	Multi-center	Both	Both	No	Yes
				amitriptyline	No	122	45.3 (*)	*	50-150	Flexible	76	HAMD 21	23.60								
Murasaki 2010a (iQWIG22532, Schoemaker 2002)	2002	2	2	mirtazapine	Yes	104	42 (12.1)	0.68	15-45	Flexible	23	HAMD 17	25.10	6	DSM-IV	Europe	Multi-center	Both	Outpatients only	No	Yes
				fluvoxamine	No	105	39.4 (12.7)	0.64	50-150	Flexible	78	HAMD 17	25.10								
Murasaki 2010b (iQWIG9902, Schoemaker 2002)	2002	2	2	mirtazapine	Yes	101	40.7 (11.8)	0.50	15-45	Flexible	*	HAMD 17	22.90	6	DSM-IV	Asia	Multi-center	Both	Outpatients only	No	Yes
				fluvoxamine	No	102	42.2 (12.9)	0.39	50-150	Flexible	*	HAMD 17	22.50								
	unpublished	2	3	paroxetine	Yes	4	49.3 (*)	1.00	30-30	Fixed	30	HAMD 21	*	4	DSM-IV	Europe	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear

MY-1008/BRL-029060/2/CPMS-076				placebo	No	4	46.5 (*)	0.50	0-0	Fixed	0	HAMD 21	*							
MY-1042/BRL-029060/CPMS-251	unpublished	2	2	paroxetine	Yes	125	41.7 (11.3)	*	20-50	Flexible	*	HAMD unspecified	24.47	8	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	129	42 (10.5)	*	0-0	Flexible	0	HAMD unspecified	24.35								
MY-1043/BRL-029060/115	unpublished	3	3	paroxetine	Yes	284	42.3 (12.5)	*	20-50	Flexible	*	HAMD 21	*	12	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				fluoxetine	No	289	41.7 (11.3)	*	20-80	Flexible	*	HAMD 21	*								
				placebo	No	118	42.1 (11.6)	*	0-0	Flexible	0	HAMD 21	*								
MY-1045/BRL-029060/1 (PAR128)	unpublished	3	3	paroxetine	Yes	357	42.3 (12.6)	*	20-50	Flexible	*	HAMD 21	25.60	12	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				fluoxetine	No	351	40.6 (11.6)	*	20-80	Flexible	*	HAMD 21	25.60								
				placebo	No	140	43.3 (12.2)	*	0-0	Flexible	0	HAMD 21	25.70								
Mynors-Wallis 1995	1995	2	3	amitriptyline	No	31	37.2 (11.4)	*	150-150	Fixed	139	HAMD 17	19.1	12	RDC	Europe	Single center	Primary care	Outpatients only	Unclear	Unclear
				placebo	No	30	37 (10.4)	*	0-0	Fixed	0	HAMD 17	18.4								
NCT00822744 (EudraCT Number2008-001718-26)	unpublished	2	5	escitalopram	Unclear	103	*	*	10-10	Fixed	10	HAMD 17	*	8	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				placebo	No	106	*	*	0-0	Fixed	0	HAMD 17	*								
NCT01020799	unpublished	2	3	escitalopram	No	50	36.22 (11.3)	0.44	20-20	Fixed	20	HAMD unspecified	24.40	4	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				placebo	No	99	41.77 (10.0)	0.49	0-0	Fixed	0	HAMD unspecified	24.60								
NCT01145755	unpublished	2	3	duloxetine	No	47	39.9 (*)	0.51	60-60	Fixed	60	MADRS	*	6	*	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				placebo	No	44	38.4 (*)	0.68	0-0	Fixed	0	MADRS	*								
NCT01254305	Unpublished	2	3	placebo	No	93	41.4 (12)	0.65	0-0	Flexible	0	*	*	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				levomilnacipran	Yes	90	42.9 (12.6)	0.58	40-120	Flexible	*	*	*								
NCT01255787 (EUCTR2010-022257-41, Lu AA21004/CCT-002, U1111-1117-6595, JapicCTI-101344, CTRI/2011/08/001963)	Unpublished	4	4	placebo	No	152	43.6 (11.6)	0.60	0-0	Fixed	0	MADRS	31.60	8	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				vortioxetine	Yes	144	44.2 (11.9)	0.68	5-5	Fixed	5	MADRS	31.60								
				vortioxetine	Yes	150	45.7 (10.9)	0.62	10-10	Fixed	10	MADRS	31.80								
				vortioxetine	Yes	154	44 (11.8)	0.60	20-20	Fixed	20	MADRS	31.70								
NCT01355081(japicCTI-111492, U1111-1120-9277)	Unpublished	3	3	vortioxetine	Yes	119	38.8 (10.8)	0.42	5-5	Fixed	5	HAMD 17	20.90	8	DSM-IV	Asia	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				vortioxetine	Yes	123	38.8 (11)	0.44	10-10	Fixed	10	HAMD 17	21.20								
				placebo	No	124	37.6 (10.7)	0.54	0-0	Fixed	0	HAMD 17	21.50								

NCT01808612	unpublished	3	3	fluoxetine	Yes	169	40.5 (11.2)	0.49	20-20	Fixed	20	HAMD 21	*	6	*	Asia	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	Yes	84	39.58 (10.6)	0.40	40-40	Fixed	40	HAMD 21	*								
				placebo	No	260	38.54 (11.6)	0.50	0-0	Fixed	0	HAMD 21	*								
Nemeroff 1995	1995	2	2	fluvoxamine	Yes	49	38.5 (*)	*	50-150	Flexible	124	HAMD 21	24.57	7	DSM-III-R	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Yes	Yes
				sertraline	No	48	41.2 (*)	*	50-200	Flexible	137	HAMD 21	23.15								
Nemeroff 2007	2007	3	3	fluoxetine	Unclear	104	37.9 (11.5)	*	20-60	Flexible	41	HAMD 21	23.70	6	DSM-IV	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Yes	Unclear
				venlafaxine	Yes	102	40.1 (11.1)	*	75-225	Flexible	142	HAMD 21	23.50								
				placebo	No	102	40.4 (11.7)	*	0-0	Flexible	0	HAMD 21	23.70								
Newhouse 2000	2000	2	2	sertraline	Yes	117	68 (5.3)	*	50-100	Flexible	72	HAMD 24	25.10	12	DSM-III-R	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Yes	Yes
				fluoxetine	No	119	67 (5.9)	*	20-40	Flexible	29	HAMD 24	25.00								
Nierenberg 2007 (F1J-MC-HMCR, NCT00073411, Pigott 2007)	2007	3	3	escitalopram	No	274	43.3 (13)	*	10-10	Fixed	10	HAMD 17	17.80	8	DSM-IV	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Yes	Unclear
				duloxetine	Yes	273	41.1 (11.6)	*	60-60	Fixed	60	HAMD 17	17.60								
				placebo	No	137	42.5 (12.3)	*	0-0	Fixed	0	HAMD 17	17.70								
Ninan 2003 (poster SCT-MD-26)	unpublished	2	2	escitalopram	Yes	154	37.8 (11.6)	*	10-20	Flexible	*	MADRS	30.40	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				placebo	No	155	39 (11.6)	*	0-0	Flexible	0	MADRS	30.50								
NKD20006 (NCT00048204)	unpublished	2	3	paroxetine	Yes	125	37.9 (11.9)	0.63	20-20	Fixed	20	HAMD 17	24.70	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	No
				placebo	No	125	38 (11.3)	0.56	0-0	Fixed	0	HAMD 17	24.50								
Noguera 1991	1991	2	2	clomipramine	No	60	46 (*)	*	100-100	Fixed	100	HAMD unspecified	24.60	6	DSM-III	Europe	Multi-center	Secondary/Tertiary care	Other/Unclear	Yes	Yes
				fluoxetine	Yes	60	46.3 (*)	*	20-40	Flexible	*	HAMD unspecified	24.30								
Norton 1984	1984	2	3	fluvoxamine	Yes	35	39.2 (*)	*	100-*	Flexible	133	HAMD 17	19.50	4	RDC	Europe	Multi-center	Secondary/Tertiary care	Outpatients only	No	Yes
				placebo	No	25	38.8 (*)	*	0-0	Flexible	0	HAMD 17	19.90								
Oakes 2012a (NCT00536471)	2012	2	2	duloxetine	Yes	257	42.2 (12.2)	0.60	60-60	Fixed	60	HAMD 17	22.90	36	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				placebo	No	127	43.7 (12.5)	0.61	0-0	Fixed	0	HAMD 17	22.80								
Oakes 2012b (NCT00536471)	2012	2	2	duloxetine	Yes	261	44.7 (12.2)	0.65	60-60	Fixed	60	HAMD 17	22.80	36	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear

				placebo	No	131	43.9 (11.9)	0.66	0-0	Fixed	0	HAMD 17	22.90							
Olie 1997	1997	2	2	sertraline	Yes	129	43.6 (11.4)	0.61	50-200	Flexible	*	HAMD 17	25.4	6	DSM-III-R	Europe	Unclear	Other/Unclear	Outpatients only	Yes	Yes
				placebo	No	129	43.9 (12.1)	0.65	0-0	Flexible	0	HAMD 17	25.5							
Olie 2007 (CL3-20098-042)	2004	2	2	agomelatine	Yes	118	44.3 (11.5)	0.72	25-50	Flexible	*	HAMD 17	27.40	6	DSM-IV	Europe	Multi-center	Secondary /Tertiary care	Both	No	No
				placebo	No	120	45.6 (11.1)	0.75	0-0	Flexible	0	HAMD 17	27.20							
Ontiveros 1994 (MY-0144/BRL 29060/1/CPMS-135, PAR135)	1994	2	2	paroxetine	No	60	43.1 (11)	*	20-20	Fixed	20	HAMD 21	26.20	6	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	No
				fluoxetine	No	62	38.7 (10.7)	*	20-20	Fixed	20	HAMD 21	26.40							
OntiverosSanchez 1998	1998	2	2	fluoxetine	Yes	21	38.6 (11.5)	0.43	20-20	Fixed	20	HAMD 17	23.50	6	DSM-III-R	South America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				amitriptyline	No	21	36.5 (9.34)	0.62	150-250	Flexible	160	HAMD 17	23.10							
Ottevanger 1995	1995	2	2	fluvoxamine	Yes	20	51.3 (15.39)	*	100-300	Flexible	204	HAMD 17	26.40	4	Feighner	Europe	Multi-center	Other/Unclear	Inpatients only	Unclear	Yes
				clomipramine	No	20	47.05 (12.4)	*	50-150	Flexible	106	HAMD 17	25.70							
Ou 2010	2010	2	2	citalopram	Unclear	120	36.4 (12.3)	0.54	20-40	Flexible	28	HAMD 17	22.9	6	DSM-IV	Asia	Multi-center	Secondary /Tertiary care	Both	Unclear	Yes
				escitalopram	Unclear	120	36.7 (12.5)	0.58	10-20	Flexible	14	HAMD 17	23.4							
PAR 01 001 (GSK & FDA)	1989	2	2	paroxetine	Yes	25	42.1 (*)	0.35	10-50	Flexible	27	HAMD 21	27.90	6	DSM-III	North America	Single center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	25	44.1 (*)	0.35	0-0	Flexible	0	HAMD 21	27.50							
PAR 279 MDUK	unpublished	2	3	paroxetine	Yes	19	39.7 (18.2)	0.68	30-30	Fixed	30	HAMD unspecified	22.80	6	*	Europe	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				placebo	No	10	51.6 (17.3)	0.70	0-0	Fixed	0	HAMD unspecified	22.30							
PAR 29060.308 (HP/81/74A)	unpublished	2	2	paroxetine	Yes	10	43.3 (12.6)	0.60	30-30	Fixed	30	*	*	6	*	Europe	Single center	Secondary /Tertiary care	Inpatients only	Yes	Unclear
				amitriptyline	No	12	45.3 (12.5)	0.58	150-150	Fixed	150	*	*							
PAR 29060.310 (HP 81/85A)	unpublished	2	2	paroxetine	Yes	10	39.1 (11.9)	0.67	30-30	Fixed	30	*	*	7	*	Europe	Single center	Other/Unclear	Other/Unclear	Yes	Unclear
				amitriptyline	No	13	43.7 (10.2)	0.50	150-150	Fixed	150	*	*							
PAR 29060.314 (HP 82/134)	unpublished	2	2	paroxetine	Yes	10	46.8 (13.1)	0.30	30-30	Fixed	30	*	*	6	*	Europe	Single center	Other/Unclear	Other/Unclear	Yes	Unclear
				amitriptyline	No	8	41.8 (11.7)	0.75	150-150	Fixed	150	*	*							
PAR 29060.316 (HP/82/47A)	unpublished	2	2	paroxetine	Yes	9	47.2 (14.8)	0.78	30-30	Fixed	30	*	*	7	RDC	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Unclear

				amitriptyline	No	8	41 (11.7)	1.00	150-150	Fixed	150	*	*							
PAR 29060.318 (HP/82/64A)	unpublished	2	2	paroxetine	Yes	9	47.3 (10.1)	1.00	30-30	Fixed	30	*	*	7	*	Europe	Single center	Secondary Tertiary care	Inpatients only	Yes	Unclear
				amitriptyline	No	12	50.1 (8.2)	1.00	150-150	Fixed	150	*	*							
PAR 29060/281	unpublished	2	2	paroxetine	Yes	82	39.5 (13.1)	0.78	30-30	Fixed	30	HAMD 21	27.80	6	Feighner	Europe	Single center	Primary care	Other/Unclear	Yes	Unclear
				amitriptyline	No	80	38.1 (13.1)	0.75	75-150	Flexible	*	HAMD 21	26.60							
PAR MDUK 032	unpublished	2	2	paroxetine	Yes	29	42.6 (11.7)	*	20-30	Flexible	*	HAMD 17	24.00	6	DSM-III	*	Multi-center	Primary care	Outpatients only	Unclear	Unclear
				amitriptyline	No	30	46.2 (11.8)	*	100-150	Flexible	*	HAMD 17	23.20							
Patris 1996 (Study 91301 - FDA)	1996	2	2	fluoxetine	No	184	43 (*)	*	20-20	Fixed	20	MADRS	29.40	8	DSM-III-R	Europe	Multi-center	Primary care	Outpatients only	Yes	Unclear
				citalopram	Yes	173	44 (*)	*	20-20	Fixed	20	MADRS	29.70							
Paykel 1988	1988	2	2	amitriptyline	No	45	*	*	125-175	Flexible	111	HAMD 17	16.2	6	RDC	Europe	Multi-center	Primary care	Outpatients only	Unclear	Yes
				placebo	No	55	*	*	0-0	Flexible	0	HAMD 17	15.8							
Pelicier 1993 (PAR MDED/29060/III/86/1728M291)	1993	2	2	clomipramine	No	42	70.2 (8.9)		60-60	Fixed	60	MADRS	30.00	5	Feighner	Europe	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				paroxetine	Yes	41	71.1 (8)		20-20	Fixed	20	MADRS	29.50							
Perahia 2006 (HMAY - Study Group B)	2006	4	4	duloxetine	Yes	93	46.47 (12.7)	*	80-80	Fixed	80	HAMD 17	21.30	8	DSM-IV	Unspecified	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				duloxetine	Yes	103	43.99 (10.8)	*	120-120	Fixed	120	HAMD 17	21.38							
				paroxetine	No	97	45.81 (10.6)	*	20-20	Fixed	20	HAMD 17	21.03							
				placebo	No	99	44.67 (10.1)	*	0-0	Fixed	0	HAMD 17	20.58							
Perahia 2008a (HMBU) (NCT00071695)	2008	2	2	duloxetine	Yes	166	45.42 (13)	0.72	60-60	Fixed	60	HAMD 17	23.10	6	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				venlafaxine	No	166	42.62 (13.1)	0.69	150-150	Fixed	150	HAMD 17	23.10							
Perahia 2008b (HMCQ, NCT00067912)	2008	3	3	duloxetine	Yes	164	43.07 (12.6)	0.67	60-60	Fixed	60	HAMD 17	22.21	6	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				venlafaxine	No	169	42.46 (12.4)	0.68	75-75	Fixed	75	HAMD 17	22.51							
				venlafaxine	No	171	40.64 (11.4)	0.62	150-150	Fixed	150	HAMD 17	22.24							
Pomara 2013	2013	2	2	vilazodone	Unclear	255	*	*	40-40	Fixed	40	MADRS	*	9	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				placebo	No	253	*	*	0-0	Fixed	0	MADRS	*							
Preskorn 1991	1991	2	2	fluoxetine	Yes	30	*	*	20-60	Flexible	*	HAMD unspecified	23.8	6	DSM-III	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				amitriptyline	No	31	*	*	50-200	Flexible	*	HAMD unspecified	23.5							

PZ/109	unpublished	2	2	sertraline	Yes	104	*	0.60	*	Flexible	*	HAMD 17	22.00	8	*	*	*	*	*	*	*
				placebo	No	103	*	0.66	*	Flexible	*	HAMD 17	21.50								
PZ/111	unpublished	3	3	fluoxetine	No	108	*	0.67	*	Flexible	*	HAMD 17	24.40	8	*	*	*	*	*	*	*
				sertraline	Yes	106	*	0.75	*	Flexible	*	HAMD 17	24.1								
				placebo	No	105	*	0.65	*	Flexible	*	HAMD 17	24.2								
Quera-Salva 2010 (CL3-20098-056)	2010	2	2	agomelatine	Yes	71	41.3 (12.4)	*	25-50	Flexible	*	HAMD 17	26.10	25	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	No
				escitalopram	No	67	41.4 (10.7)	*	10-20	Flexible	*	HAMD 17	26.10								
Raft 1981	1981	2	3	amitriptyline	No	12	*	*	100-300	Flexible	235	HAMD17	29.66	5	Feighner	North America	Single center	Secondary /Tertiary care	Inpatients only	Unclear	Unclear
				placebo	No	7	*	*	0-0	Flexible	0	HAMD 17	27.2								
Rapaport 1996	1996	2	2	fluvoxamine	Yes	51	40 (*)	*	100-150	Flexible	102	HAMD 21	25.20	7	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				fluoxetine	No	49	38.6 (*)	*	20-80	Flexible	34	HAMD 21	25.60								
Rapaport 2003 (PAR487)	2003	3	3	paroxetine	Yes	104	70.39 (5.93)	*	12.5-50	Flexible	30	HAMD 17	22.10	12	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				paroxetine	Yes	106	70.05 (6.59)	*	10-40	Flexible	26	HAMD 17	22.30								
				placebo	No	109	69.39 (5.4)	*	0-0	Flexible	0	HAMD 17	22.10								
Rapaport 2009 (BRL-29060/874) (NCT00067444)	2009	2	3	paroxetine	Yes	177	67 (6.56)	*	25-25	Fixed	25	HAMD 17	22.74	10	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	180	68 (6.7)	*	0-0	Fixed	0	HAMD 17	22.41								
Raskin 2007 (HMBV, NCT00062673)	2007	2	2	duloxetine	Yes	207	72.63 (5.65)	0.60	60-60	Fixed	60	HAMD 17	18.76	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				placebo	No	104	73.33 (5.73)	0.58	0-0	Fixed	0	HAMD 17	18.94								
Ravindran 1995	1995	2	3	sertraline	Yes	40	38.8 (10.9)	0.65	50-200	Flexible	*	HAMD 17	20.7	8	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	26	39 (9.7)	0.58	0-0	Flexible	0	HAMD 17	21								
Ravindran 1997 (MY-1055/BRL-029060/1/CPMS-245 PAR 245)	1997	2	2	paroxetine	Yes	513	43.3 (13)	0.73	20-40	Flexible	*	MADRS	29.7	12	Other operationalized	Cross-Continental	Multi-center	Primary care	Other/Unclear	Yes	Yes
				clomipramine	No	506	42 (12.5)	0.73	75-150	Flexible	*	MADRS	29.1								
Reimherr 1990 (SER 104 - FDA)	1990	3	3	amitriptyline	No	149	37.9 (*)	*	50-150	Flexible	104	HAMD 17	23.18	8	DSM-III	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	No
				placebo	No	150	40.1 (*)	*	0-0	Flexible	0	HAMD 17	23.43								
				sertraline	Unclear	149	39 (*)	*	50-200	Flexible	145	HAMD 17	23.28								

Reimherr 1998 (WELL203, FDA203)	1998	2	3	placebo	No	121	40.2 (12.2)	*	0-0	Fixed	0	HAMD 17	23.21	8	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				bupropion	Yes	120	38.6 (10.7)	*	300-300	Fixed	300	HAMD 17	23.41								
Remick 1994	1994	2	2	amitriptyline	No	17	41 (*)	*	50-300	Flexible	135	HAMD 17	23.50	7	DSM-III	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Yes	Unclear
				fluvoxamine	Yes	16	41.7 (*)	*	50-300	Flexible	175	HAMD 17	23.80								
Rickels 1982	1982	3	3	amitriptyline	No	68	40 (13)	*	75-200	Flexible	140	HAMD 21	26.46	6	DSM-III	North America	Single center	Both	Outpatients only	Unclear	Unclear
				placebo	No	68	40 (13)	*	0-0	Flexible	0	HAMD 21	26.46								
				trazodone	Unclear	66	40 (13)	*	150-400	Flexible	275	HAMD 21	26.46								
Rickels 1985	1985	2	4	amitriptyline	No	124	39 (11.7)	*	50-225	Flexible	148	HAMD 21	25.48	6	DSM-III	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Yes	No
				placebo	No	130	39 (11.7)	*	0-0	Flexible	0	HAMD 21	26.38								
Rickels 1994 (FDA CN104-005)	1994	2	3	nefazodone	Yes	96	44.7 (13.5)	0.68	100-600	Flexible	375	HAMD 17	24.40	8	DSM-III-R	North America	Multi-center	Both	Outpatients only	Unclear	Yes
				placebo	No	95	42.6 (13.5)	0.60	0-0	Flexible	0	HAMD 17	23.50								
Rickels 1995 (FDA CN104-006-1)	1995	2	3	nefazodone	Yes	45	*	*	200-600	Flexible	419	HAMD 17	24.20	8	DSM-III-R	North America	Single center	Other/Unclear	Outpatients only	Unclear	No
				placebo	No	44	*	*	0-0	Flexible	0	HAMD 17	24.20								
Rickels 2009 (GNSC-04-DP-02, NCT00285376)	2009	2	2	vilazodone	Yes	205	40 (12.1)	*	40-40	Fixed	40	HAMD 17	24.80	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				placebo	No	205	39.8 (12.7)	*	0-0	Fixed	0	HAMD 17	24.90								
Robinson 2014 (NCT00406848)	2014	2	2	duloxetine	Yes	249	73.01 (6.26)	0.66	60-60	Fixed	60	HAMD 17	19.40	24	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				placebo	No	121	73.1 (5.64)	0.59	0-0	Fixed	0	HAMD 17	19.30								
Roffman 1982	1982	2	3	amitriptyline	No	95	42.55 (12.3)	*	75-225	Fixed	225	HAMD 21	24.2	4	DSM-III	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				placebo	No	94	44.66 (12.1)	*	0-0	Fixed	0	HAMD 21	24.5								
Roose 2004 (CIT-MD-03)	2004	2	2	citalopram	Yes	87	79.9 (4)	0.54	10-40	Flexible	*	HAMD 24	24.40	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	91	79.3 (4.7)	0.62	0-0	Flexible	0	HAMD 24	24.20								
Ropert 1989	1989	2	2	fluoxetine	Unclear	71	42.7 (11)	0.60	20-20	Fixed	20	HAMD 21	23.00	6	DSM-III	Europe	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				clomipramine	No	72	44.8 (12.6)	0.69	75-75	Fixed	75	HAMD 21	23.00								
Rossini 2005	2005	2	2	fluvoxamine	Unclear	40	67.8 (*)	*	200-200	Fixed	200	HAMD 21	31.23	7	DSM-IV	Europe	Single center	Secondary/Tertiary care	Inpatients only	Unclear	Yes
				sertraline	Unclear	48	68.2 (*)	*	150-150	Fixed	150	HAMD 21	29.23								

Roth 1990	1990	2	3	fluvoxamine	Yes	30	42.8 (11.1)	0.67	100-300	Flexible	218	HAMD unspecified	28.3	6	DSM-III	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	30	43.9 (11.3)	0.52	0-0	Flexible	0	HAMD unspecified	28.9								
Rouillon 1991 (Limosin 2006, 029060/1/CPMS 069 1991)	1991	2	2	paroxetine	Yes	45	71.8 (7.4)	0.87	20-50	Other/Unclear	*	HAMD 21	27	6	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Unclear
				clomipramine	No	47	70.8 (6.5)	0.91	50-150	Other/Unclear	*	HAMD 21	27.6								
Rowan 1980	1980	2	3	amitriptyline	No	44	*	*	75-187.5	Flexible	*	HAMD 17	*	6	RDC	Europe	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	45	*	*	0-0	Flexible	0	HAMD 17	*								
Rudolph 1998 (VEN 600A-203 (FDA)	1998	4	4	venlafaxine	Yes	89	43.6 (10.9)	0.40	75-75	Fixed	75	HAMD 21	26.00	6	DSM-III	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				venlafaxine	Yes	89	43.1 (9.61)	0.43	225-225	Fixed	225	HAMD 21	26.00								
				venlafaxine	Yes	88	43.8 (10.3)	0.33	375-375	Fixed	375	HAMD 21	24.90								
				placebo	No	92	41.5 (11.3)	0.32	0-0	Fixed	0	HAMD 21	25.30								
Rudolph 1999	1999	3	3	fluoxetine	No	103	40 (*)	*	20-60	Flexible	47	HAMD 21	26.00	8	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				venlafaxine	Yes	100	40 (*)	*	75-225	Flexible	175	HAMD 21	25.00								
				placebo	No	98	40 (*)	*	0-0	Flexible	0	HAMD 21	25.00								
Rush 1998 (excluding Armitage 1997 and Gillin 1997)	1998	2	2	nefazodone	Yes	*	*	*	200-500	Flexible	*	HAMD 17	*	8	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	No	*	*	*	20-40	Flexible	*	HAMD 17	*								
Rush 2001	2001	2	2	bupropion	Yes	122	39 (*)	0.48	100-300	Flexible	259	HAMD 21	24.8	16	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				sertraline	No	126	40 (*)	0.48	50-200	Flexible	123	HAMD 21	24.8								
Sacchetti 2002 (BRL-29060/109)	2002	2	2	paroxetine	Yes	64	48.7 (*)	0.64	20-50	Flexible	*	HAMD 21	25.4	12	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				amitriptyline	No	65	50.5 (*)	0.66	100-250	Flexible	*	HAMD 21	26.2								
Sambunaris 2014 (LVM-MD-03, NCT01034462)	2014	2	2	placebo	No	220	44.6 (13.9)	0.66	0-0	Flexible	0	HAMD 17	22.90	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				levomilnacipran	Yes	222	45 (13.2)	0.65	40-120	Flexible	73	HAMD 17	23.30								
Samuelian 1998	1998	2	2	venlafaxine	Yes	52	47 (12)	*	100-150	Flexible	105	HAMD 21	27.80	6	DSM-III-R	Europe	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				clomipramine	No	50	47 (11)	*	100-150	Flexible	105	HAMD 21	27.80								
Sauer 2003	2003	2	2	venlafaxine	Yes	79	48.5 (10.8)	*	75-150	Flexible	85	HAMD 21	23.60	6	ICD-10	Europe	Multi-center	Both	Outpatients only	Unclear	No
				amitriptyline	No	77	46 (10.9)	*	75-150	Flexible	84	HAMD 21	23.64								

Schatzberg 2002 (003-901)	2002	2	2	mirtazapine	Yes	128	71.7 (5.7)	*	15-45	Flexible	34	HAMD 17	22.20	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Yes
				paroxetine	No	126	72 (5.1)	*	20-40	Flexible	34	HAMD 17	22.40								
Schatzberg 2006a	2006	3	3	fluoxetine	No	100	71 (*)	*	20-60	Flexible	*	HAMD 21	24.00	8	DSM-IV	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				venlafaxine	Yes	104	71 (*)	*	75-225	Flexible	*	HAMD 21	24.00								
			3	placebo	No	96	71 (*)	*	0-0	Flexible	0	HAMD 21	23.00								
Schneider 2003	2003	2	2	sertraline	Yes	371	70 (6.8)	0.54	50-100	Flexible	82	HAMD 17	21.40	8	DSM-IV	North America	Multi-center	Both	Outpatients only	Yes	Yes
				placebo	No	376	69.6 (6.5)	0.58	0-0	Flexible	0	HAMD 17	21.40								
Schoene 1993 (Geretsegger 1994 MY1021/BRC)	1993	2	2	paroxetine	Yes	54	74.3 (6)	*	20-50	Flexible	*	HAMD 21	29.00	6	DSM-III-R	Europe	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				fluoxetine	No	52	73.7 (6.4)	*	20-80	Flexible	*	HAMD 21	27.90								
Schwartz 2002 (iQWIG)	2002	2	2	reboxetine	Unclear	80	41.9 (*)	0.71	8-10	Flexible	*	HAMD 17	28.60	8	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				venlafaxine	Unclear	87	42.2 (*)	0.67	225-375	Flexible	*	HAMD 17	28.80								
Schweizer 1994 (VEN 600A-301 FDA)	1994	2	3	venlafaxine	Yes	76	41 (13)	0.71	150-225	Flexible	179	HAMD 21	25.39	6	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	78	42 (12)	0.67	0-0	Flexible	0	HAMD 21	24.56								
SCT-MD-09	unpublished	2	2	escitalopram	Yes	16	35.9 (10.6)	*	10-20	Fixed	*	*	*	5	DSM-IV	North America	Single center	Other/Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	No	14	41.4 (9.8)	*	20-40	Fixed	*	*	*								
SCT-MD-49 (NCT00668525)	unpublished	3	3	escitalopram	Yes	325	41.4 (12.3)	0.64	10-10	Fixed	10	HAMD 24	29.30	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				escitalopram	Yes	332	40.4 (11.9)	0.69	28-28	Fixed	28	HAMD 24	29.30								
				placebo	No	220	42.3 (12.7)	0.63	*	Fixed	*	HAMD 24	28.90								
Sechter 1999	1999	2	2	sertraline	Yes	118	43.4 (12.3)	*	50-150	Flexible	77	HAMD 17	24.50	8	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	No	Unclear
				fluoxetine	No	120	42.5 (11.1)	*	20-60	Flexible	34	HAMD 17	24.90								
Sechter 2004	2004	2	2	milnacipran	Yes	149	44.8 (11.6)	*	100-100	Fixed	100	HAMD 17	23.70	6	DSM-IV	Europe	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Unclear
				paroxetine	No	153	42.8 (11.2)	*	20-20	Fixed	20	HAMD 17	23.40								
SER 101 (FDA)	unpublished	4	5	sertraline	Yes	26	*	*	50-50	Fixed	50	HAMD 17	*	4	DSM-III	North America	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Unclear
				sertraline	Yes	24	*	*	100-100	Fixed	100	HAMD 17	*								
				sertraline	Yes	23	*	*	200-200	Fixed	200	HAMD 17	*								

				placebo	No	26	*	*	0-0	Fixed	0	HAMD 17	*						
SER 310 (FDA)	unpublished	4	4	sertraline	Yes	33	*	*	50-50	Fixed	50	*	*	4	DSM-III	Europe	Multi-center	Secondary/Tertiary care	Inpatients only	Yes	Yes
				sertraline	Yes	35	*	*	100-100	Fixed	100	*	*								
				sertraline	Yes	37	*	*	200-200	Fixed	200	*	*								
				placebo	No	34	*	*	0-0	Fixed	0	*	*								
SER 315 (FDA)	unpublished	3	3	sertraline	Yes	85	41 (*)	0.66	50-200	Flexible	105	HAMD 17	23.10	8	DSM-III	Europe	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				amitriptyline	No	77	44 (*)	0.71	50-200	Flexible	82	HAMD 17	23.50								
				placebo	No	80	43 (*)	0.78	0-0	Flexible	0	HAMD 17	22.20								
SER-CHN-1	unpublished	2	2	paroxetine	Yes	113	40.14 (13.2)	0.55	20-30	Flexible	*	HAMD unspecified	27.10	6	DSM-III-R	Asia	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				amitriptyline	No	118	40.54 (13.45)	0.53	150-150	Fixed	150	HAMD unspecified	26.60								
Settle 1999 (WELL212)	1999	2	3	bupropion	Yes	150	37.2 (11.3)	*	100-300	Flexible	*	HAMD 21	24.40	8	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	No
				placebo	No	154	38.2 (11.4)	*	0-0	Flexible	0	HAMD 21	23.88								
Shaw 1986	1986	2	2	citalopram	Unclear	24	*	*	30-60	Flexible	46	HAMD 17	25.67	6	DSM-III	Europe	Multi-center	Secondary/Tertiary care	Both	Unclear	Yes
				amitriptyline	Unclear	20	*	*	112.5-225	Flexible	148	HAMD 17	26.48								
Sheehan 2009a	2009	3	3	fluoxetine	No	99	37.8 (11.1)	0.69	60-80	Flexible	61	HAMD 21	29.50	6	DSM-IV	North America	Multi-center	Secondary/Tertiary care	Inpatients only	Yes	Yes
				venlafaxine	Yes	95	41.7 (12.8)	0.48	225-375	Flexible	298	HAMD 21	29.90								
				placebo	No	95	39.9 (13)	0.64	0-0	Flexible	0	HAMD 21	29.40								
Sheehan 2009b (NCT00775203)	2009	2	2	trazodone	Yes	206	43.8 (12.8)	0.64	150-375	Flexible	310	HAMD 17	23.20	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	No	No
				placebo	No	206	44 (13.5)	0.64	0-0	Flexible	0	HAMD 17	22.40								
Shelton 2006 (NCT00179283)	2006	2	2	venlafaxine	Unclear	78	37.2 (11.6)	*	75-225	Flexible	*	HAMD 17	22.40	8	DSM-IV	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Unclear	No
				sertraline	Yes	82	41.2 (12)	*	50-150	Flexible	*	HAMD 17	22.10								
Shipley 1981	1981	2	2	amitriptyline	No	53	39 (13.1)	*	200-200	Fixed	200	HAMD 17	38.5	4	RDC	North America	Single center	Secondary/Tertiary care	Inpatients only	Yes	Unclear
				placebo	No	23	40.3 (13.9)	*	0-0	Fixed	0	HAMD 17	44.2								
Shu 2014 (CL3-20098-052, ChiCTR-TRC-11001668)	2014	2	2	agomelatine	Yes	314	39.2 (12.8)	0.68	25-50	Flexible	*	HAMD 17	26.80	8	DSM-IV	Asia	Multi-center	Primary care	Outpatients only	No	No
				fluoxetine	No	314	38.9 (12.6)	0.71	20-40	Flexible	*	HAMD 17	26.80								

Silverstone 1999	1999	3	3	fluoxetine	No	121	43.2 (10.9)	*	20-60	Flexible	40	HAMD 21	27.20	12	DSM-IV	*	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				venlafaxine	Yes	128	41.1 (12)	*	75-225	Flexible	141	HAMD 21	27.20								
				placebo	No	119	41.6 (10.8)	*	0-0	Flexible	0	HAMD 21	27.20								
Sir 2005	2005	2	2	venlafaxine	No	84	36.8 (12.4)	*	75-225	Flexible	161	HAMD 17	23.50	8	DSM-IV	Cross-Continental	Multi-center	Secondary /Tertiary care	Outpatients only	Unclear	Unclear
				sertraline	Yes	79	37.3 (13.5)	*	50-150	Flexible	105	HAMD 17	23.40								
Smeraldi 1998	1998	3	3	venlafaxine	Unclear	55	71 (6)	*	75-150	Flexible	*	*	*	6	DSM-III-R	Europe	Multi-center	Other/Unclear	Both	Yes	Unclear
				clomipramine	Unclear	58	71 (6)	*	50-100	Flexible	*	*	*								
				trazodone	Unclear	57	71 (6)	*	150-300	Flexible	*	*	*								
Smith 1990 (MIR 003-024 FDA)	1990	3	3	mirtazapine	Yes	50	*	*	10-35	Flexible	18	HAMD 21	27.50	6	DSM-III	North America	Unclear	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				amitriptyline	No	50	*	*	80-280	Flexible	111	HAMD 21	27.60								
				placebo	No	50	*	*	0-0	Flexible	0	HAMD 21	27.70								
Sramek 1995	1995	2	3	fluoxetine	No	72	33.9 (*)	0.60	20-20	Fixed	20	HAMD 24	28.20	9	DSM-III-R	North America	Single center	Other/Unclear	Other/Unclear	Yes	Unclear
				placebo	No	72	33.9 (*)	0.60	0-0	Fixed	0	HAMD 24	27.50								
Stahl 2000	2000	3	3	citalopram	Yes	107	39.1 (*)	*	20-60	Flexible	57	HAMD 21	26.50	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				sertraline	Unclear	108	39.5 (*)	*	50-150	Flexible	143	HAMD 21	26.60								
				placebo	No	108	37.3 (*)	*	0-0	Flexible	0	HAMD 21	26.40								
Stahl 2010 (CAGO178A2302)	2010	3	3	agomelatine	Yes	168	43.2 (11.82)	0.68	25-25	Fixed	25	HAMD 17	26.80	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	No
				agomelatine	Yes	169	43.8 (11.96)	0.64	50-50	Fixed	50	HAMD17	26.80								
				placebo	No	166	43 (13.11)	0.65	0-0	Fixed	0	HAMD 17	26.40								
Staner 1995 (063)	1995	2	2	paroxetine	Yes	21	41.7 (10.8)	*	30-30	Fixed	30	HAMD 21	26.00	5	RDC	Europe	Single center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				amitriptyline	No	19	42.5 (11.7)	*	150-150	Fixed	150	HAMD 21	24.00								
Stark 1985 (Study 27 - FDA)	1985	2	3	fluoxetine	Yes	185	40 (*)	0.68	20-80	Flexible	69	HAMD 21	27.50	6	DSM-III	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	169	41 (*)	0.67	0-0	Flexible	0	HAMD 21	28.10								

Stratas 1984	1984	2	3	amitriptyline	No	12	*	*	50-300	Flexible	179	HAMD 21	*	6	RDC	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				placebo	No	10	*	*	0-0	Flexible	0	HAMD 21	*								
Studie009 (CTN009-FCE20124)	unpublished	2	2	reboxetine	Yes	26	45.81 (11.3)	0.65	8-8	Fixed	8	HAMD 17	25.33	4	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Yes
				placebo	No	24	47.04 (13.5)	0.67	0-0	Fixed	0	HAMD 17	25.27								
Studie032 (M2020/0032)	unpublished	2	2	reboxetine	Yes	43	40.65 (14.6)	0.63	8-10	Flexible	8	HAMD 21	27.23	8	DSM-IV	Asia	Multi-center	Secondary /Tertiary care	Both	Yes	Yes
				fluoxetine	No	42	35.98 (12.7)	0.62	20-40	Flexible	27	HAMD 21	28.33								
Study 015	unpublished	2	3	reboxetine	Yes	112	45.9 (12.7)	0.63	8-10	Flexible	9	HAMD 21	27.50	6	DSM-III-R	Cross-Continental	Multi-center	Secondary /Tertiary care	Both	Unclear	Yes
				placebo	No	112	43.3 (11.7)	0.48	0-0	Flexible	0	HAMD 21	27.10								
Study 032a (CTN032-FCE20124)	unpublished	2	2	reboxetine	Yes	24	79.75 (7.11)	0.79	4-6	Flexible	*	HAMD 21	23.20	8	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Yes
				placebo	No	26	80.15 (4.51)	0.77	0-0	Flexible	0	HAMD 21	23.10								
Study 043	2006	2	2	reboxetine	Yes	183	42.8 (13.3)	0.69	8-10	Flexible	9	HAMD 21	27.40	24	DSM-IV	Europe	Multi-center	Other/Unclear	Outpatients only	Unclear	Yes
				citalopram	No	176	41.5 (12)	0.60	20-40	Flexible	28	HAMD 21	27.40								
Study 045	unpublished	3	4	reboxetine	Yes	87	40.8 (10)	0.63	4-4	Fixed	4	HAMD 21	26.20	6	DSM-IV	Cross-Continental	Multi-center	Both	Both	No	Yes
				reboxetine	Yes	89	41.6 (10.6)	0.63	8-8	Fixed	8	HAMD 21	26.40								
				placebo	No	87	40.5 (11.2)	0.70	0-0	Fixed	0	HAMD 21	26.40								
Study 049	unpublished	2	2	reboxetine	Yes	107	39.9 (11.6)	0.55	8-10	Flexible	10	HAMD 21	25.10	6	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	No
				placebo	No	105	39.7 (11.1)	0.58	0-0	Flexible	0	HAMD 21	25.30								
Study 19 (FDA, Fabre 1985)	unpublished	2	2	fluoxetine	Yes	22	34.1 (*)	0.75	40-80	Flexible	*	HAMD 21	28.90	5	RDC	*	Single center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	25	32 (*)	0.48	0-0	Flexible	0	HAMD 21	27.40								
Study 205 (FDA, WELL 205)	unpublished	4	5	bupropion	Yes	120	39.6 (10.4)	0.57	200-200	Fixed	200	HAMD 17	23.20	8	Other operationalized	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				bupropion	Yes	120	39.9 (11.4)	0.62	300-300	Fixed	300	HAMD 17	23.60								
				bupropion	Yes	119	38.8 (11.7)	0.58	400-400	Fixed	400	HAMD 17	24.20								
				placebo	No	124	40.7 (11.6)	0.68	0-0	Fixed	0	HAMD 17	23.40								
Study 25 (FDA, Rickels 1986)	unpublished	2	2	fluoxetine	Yes	18	49.4 (*)	0.72	*-80	Other/Unclear	*	HAMD 21	25.20	5	RDC	*	Unclear	Other/Unclear	Outpatients only	Yes	Unclear

				placebo	No	24	45.7 (*)	0.83	0-0	Other/Unclear	0	HAMD 21	25.80								
Study 62a (FDA) - MILD depression (Dunlop 1990)	unpublished	4	4	fluoxetine	Yes	104	38.31 (*)	0.59	60-60	Fixed	60	HAMD 21	17.20	6	DSM-III	*	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				fluoxetine	Yes	105	39.8 (*)	0.56	40-40	Fixed	40	HAMD 21	16.83								
				fluoxetine	Yes	107	39.97 (*)	0.62	20-20	Fixed	20	HAMD 21	16.99								
				placebo	No	56	38.96 (*)	0.50	0-0	Fixed	0	HAMD 21	17.41								
Study 62b (FDA) - MODERATE depression	unpublished	4	4	fluoxetine	Yes	105	39.93 (*)	0.58	60-60	Fixed	60	HAMD 21	24.20	6	DSM-III	*	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				fluoxetine	Yes	103	41.15 (*)	0.56	40-40	Fixed	40	HAMD 21	24.19								
				fluoxetine	Yes	100	39.4 (*)	0.60	20-20	Fixed	20	HAMD 21	24.72								
				placebo	No	48	38.56 (*)	0.50	0-0	Fixed	0	HAMD 21	24.25								
Study 89306 (FDA)	unpublished	3	3	citalopram	Yes	88	*	*	20-20	Fixed	20	MADRS	32.70	6	DSM-III-R	*	Multi-center	Both	Both	Yes	Yes
				citalopram	Yes	97	*	*	40-40	Fixed	40	MADRS	31.30								
				placebo	No	89	*	*	0-0	Fixed	0	MADRS	33.14								
Study F1J-MC-HMAQ - Study Group B	unpublished	3	3	duloxetine	Yes	82	39.86 (9.8)	*	40-120	Flexible	*	HAMD 17	17.88	10	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	75	41.39 (11.8)	*	0-0	Flexible	0	HAMD 17	18.32								
				fluoxetine	No	37	39.65 (12.7)	*	20-20	Fixed	20	HAMD 17	20.03								
Szegedi 2006	2006	2	2	mirtazapine	Yes	130	*	*	45-45	Fixed	45	HAMD 17	24.60	6	DSM-IV	Europe	Multi-center	Other/Unclear	Outpatients only	No	Unclear
				venlafaxine	No	128	*	*	225-225	Fixed	225	HAMD 17	24.90								
Thase 1997 (VEN XR 209 FDA)	1997	2	2	venlafaxine	Yes	95	40 (11)	0.63	75-225	Flexible	177	HAMD 21	24.53	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				placebo	No	102	42 (12)	0.60	0-0	Flexible	0	HAMD 21	23.63								
Thase 2006 (WELL 100368)	2006	2	2	bupropion	Yes	171	37.1 (12.3)	*	150-450	Flexible	300	HAMD 17	24.90	12	DSM-IV	North America	Multi-center	Secondary/Tertiary care	Outpatients only	Unclear	Unclear
				venlafaxine	No	177	37.4 (11.6)	*	75-225	Flexible	150	HAMD 17	24.10								
Thomson 1982	1982	2	4	amitriptyline	No	31	*	*	150-150	Fixed	150	HAMD unspecified	17.35	12	RDC	Europe	Multi-center	Primary care	Outpatients only	Yes	Yes
				placebo	No	28	*	*	0-0	Fixed	0	HAMD unspecified	19.43								
Tignol 1993 (29060/087)	1993	2	2	paroxetine	Yes	89	43 (11.6)	*	20-20	Fixed	20	MADRS	30.74	6	DSM-III-R	Europe	Multi-center	Secondary/Tertiary care	Inpatients only	Yes	Unclear
				fluoxetine	No	87	45 (13.2)	*	20-20	Fixed	20	MADRS	31.60								
Timmerman 1993 (Study 89422 - FDA	1993	2	2	fluvoxamine	No	109	*	*	100-200	Flexible	*	HAMD 17	24.50	6	DSM-III-R	Europe	Multi-center	Secondary/Tertiary care	Outpatients only	Unclear	Yes

and Haffmans 1996)				citalopram	Yes	108	*	*	20-40	Flexible	*	HAMD 17	24.70							
Tollefson 1995	1995	2	2	fluoxetine	Yes	335	67.4 (5.4)	0.54	*-20	Flexible	*	HAMD 17	22.20	6	DSM-III-R	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	336	68.1 (5.9)	0.55	0-0	Flexible	0	HAMD 17	22.10								
Tomarken 2004	2004	2	2	bupropion	Yes	10	39.4 (9.8)	*	200-300	Flexible	*	HAMD 17	21.70	6	DSM-IV	North America	Single center	Secondary /Tertiary care	Outpatients only	No	Unclear
				placebo	No	9	37.5 (7.8)	*	0-0	Flexible	0	HAMD 17	21.70								
Tourian 2009 (NCT00384033)	2009	4	4	desvenlafaxine	Yes	155	41 (13)		50-50	Fixed	50	HAMD 17	23	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	No	Unclear
				desvenlafaxine	Yes	160	39 (12)		100-100	Fixed	100	HAMD 17	23								
				duloxetine	No	159	39 (12)		60-60	Fixed	60	HAMD 17	23								
				placebo	No	164	39 (13)		0-0	Fixed	0	HAMD 17	24								
Trivedi 2004 (29060/810)	2004	2	3	placebo	No	149	38.4 (11.7)	*	0-0	Fixed	0	HAMD 17	23.80	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				paroxetine	Yes	154	39.4 (10.8)	*	25-25	Fixed	25	HAMD 17	23.50								
Tsutsui 2000	2000	2	2	paroxetine	Yes	116	39.1 (13.9)	*	10-40	Flexible	32	HAMD 17	23.60	6	DSM-IV	Asia	Multi-center	Both	Both	No	Yes
				trazodone	No	109	38.5 (12.7)	*	75-200	Flexible	154	HAMD 17	24.40								
Tylee 1997	1997	2	2	fluoxetine	No	170	45.5 (14.3)	0.75	20-20	Fixed	20	HAMD 17	22.50	12	DSM-IV	Europe	Multi-center	Primary care	Outpatients only	Unclear	Unclear
				venlafaxine	Yes	171	43.5 (14)	0.68	75-75	Fixed	75	HAMD 17	22.40								
Tzanakaki 2000	2000	2	2	fluoxetine	No	54	49 (10)	*	20-60	Flexible	*	HAMD 21	27.10	6	DSM-IV	Europe	Multi-center	Secondary /Tertiary care	Both	Yes	Unclear
				venlafaxine	Yes	55	47 (11)	*	75-225	Flexible	*	HAMD 21	27.80								
Upward 1988	1988	2	2	fluoxetine	Yes	13	40 (10.6)	0.55	60-80	Flexible	75	*	*	4	*	Europe	Unclear	Other/Unclear	Outpatients only	Yes	Yes
				amitriptyline	No	14	45 (13.2)	0.58	150-200	Flexible	183	*	*								
Van de Merwe 1984	1984	3	3	amitriptyline	No	5	*	*	100-150	Flexible	*	HAMD 17	*	4	RDC	Europe	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes
				placebo	No	3	*	*	0-0	Flexible	0	HAMD 17	*								
				trazodone	Yes	6	*	*	50-300	Flexible	*	HAMD 17	*								
VanMoffaert 1995a	1995	2	2	sertraline	Yes	83	46.1 (*)	*	50-100	Flexible	*	HAMD 17	24.50	8	DSM-III-R	Europe	Multi-center	Secondary /Tertiary care	Other/Unclear	Yes	Yes
				fluoxetine	No	82	48.4 (*)	*	20-40	Flexible	*	HAMD 17	23.20								
VanMoffaert 1995b	1995	2	2	mirtazapine	Yes	100	46.1 (10.8)	0.69	24-72	Flexible	*	HAMD 17	29.2	6	DSM-III	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Yes

				trazodone	No	100	46.3 (12.6)	0.71	150-450	Flexible	*	HAMD 17	27.5							
Vartiainen 1994 (MIR 84023 FDA)	1994	2	2	mirtazapine	Yes	60	46 (*)	0.58	15-50	Flexible	33	HAMD 21	25.60	6	*	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Yes
				placebo	No	57	46 (*)	0.48	0-0	Flexible	0	HAMD 21	26.00							
VEN 600A-303 (FDA)	unpublished	2	3	venlafaxine	Yes	83	39 (*)	0.70	150-225	Flexible	185	HAMD 21	23.63	6	DSM-III-R	North America	Single center	Other/Unclear	Outpatients only	Yes	Yes
				placebo	No	82	38 (*)	0.68	0-0	Flexible	0	HAMD 21	24.59							
VEN 600A-313 (FDA)	unpublished	3	4	venlafaxine	Yes	76	38 (*)	0.70	75-75	Fixed	75	HAMD 21	25.57	6	DSM-III-R	North America	Unclear	Other/Unclear	Outpatients only	Yes	Yes
				venlafaxine	Yes	82	39 (*)	0.61	200-200	Fixed	200	HAMD 21	25.57							
				placebo	No	79	38 (*)	0.69	0-0	Fixed	0	HAMD 21	25.39							
VEN XR 367 (FDA)	unpublished	4	4	venlafaxine	Yes	83	*	0.70	75-75	Fixed	75	HAMD 21	26.49	8	DSM-III-R	Europe	Multi-center	Other/Unclear	Outpatients only	Yes	Yes
				venlafaxine	Yes	82	*	0.61	150-150	Fixed	150	HAMD 21	27.11							
				paroxetine	No	81	*	0.54	20-20	Fixed	20	HAMD 21	26.13							
				placebo	No	83	*	0.67	0-0	Fixed	0	HAMD 21	26.60							
Ventura 2007 (SCT-MD-18)	2007	2	2	escitalopram	Yes	107	40.6 (13.7)	*	10-10	Fixed	10	HAMD 24	26.80	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				sertraline	No	108	38.1 (11.5)	*	50-200	Flexible	*	HAMD 24	26.80							
Versiani 1999	1999	2	2	fluoxetine	Yes	77	41.3 (*)	0.76	20-20	Fixed	20	HAMD 21	28.40	8	DSM-IV	South America	Multi-center	Other/Unclear	Other/Unclear	Yes	No
				amitriptyline	No	80	41.3 (*)	0.76	50-250	Flexible	138	HAMD 21	27.80							
Versiani 2000 (Study 091)	2000	2	2	reboxetine	Yes	28	41.4 (*)	0.46	10-10	Fixed	10	HAMD 21	35.70	6	DSM-III-R	Cross-Continental	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	No
				placebo	No	28	39.9 (*)	0.50	0-0	Fixed	0	HAMD 21	35.10							
Versiani 2005	2005	2	2	mirtazapine	Yes	145	43 (*)	*	15-60	Flexible	*	HAMD 17	29.00	8	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Other/Unclear	Yes	No
				fluoxetine	No	149	47 (*)	*	20-40	Flexible	*	HAMD 17	28.00							
Wade 2002 (ESC Study 99001 - FDA)	2002	2	2	placebo	No	189	40 (12)	0.78	0-0	Fixed	0	MADRS	28.70	8	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	Yes	Unclear
				escitalopram	Yes	191	41 (11)	0.74	10-10	Fixed	10	MADRS	29.20							
Wade 2003 (E-1721)	2003	2	2	mirtazapine	Yes	99	40 (14.3)	*	15-45	Flexible	35	HAMD 17	23.80	12	DSM-IV	Europe	Multi-center	Primary care	Outpatients only	No	No
				paroxetine	No	98	40 (11.7)	*	10-30	Flexible	24	HAMD 17	24.40							
Wade 2007 (Study 10990)	2007	2	2	escitalopram	Yes	144	43.3 (11.6)	*	20-20	Fixed	20	HAMD 17	22.70	8	DSM-IV	Cross-Continental	Multi-center	Primary care	Outpatients only	No	Unclear
				duloxetine	No	151	44.5 (11)	*	60-60	Fixed	60	HAMD 17	22.70							
Walczak 1996	1996	4	5	fluvoxamine	Yes	101	*	*	50-50	Fixed	50	HAMD 21	*	6	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	No

				fluvoxamine	Yes	100	*	*	100-100	Fixed	100	HAMD 21	*							
				fluvoxamine	Yes	99	*	*	150-150	Fixed	150	HAMD 21	*							
				placebo	No	200	*	*	0-0	Fixed	0	HAMD 21	*							
Wang 2014 (EUCTR2005-005052-40, NCT00351169, D1448C00004)	2014	2	3	escitalopram	No	157	40.3 (12.5)	0.75	10-20	Flexible	11	HAMD unspecified	27.20	8	DSM-IV	Cross-Continental	Multi-center	Other/Unclear	Other/Unclear	Unclear	Yes
				placebo	No	157	39.7 (11.1)	0.67	0-0	Flexible	0	HAMD unspecified	26.60							
Wang 2015 (NCT01571453, KCT0000432, 13926A)	2015	2	2	vortioxetine	Yes	213	39.6 (12.4)	0.58	10-10	Fixed	10	MADRS	32.30	8	DSM-IV	Asia	Multi-center	Secondary /Tertiary care	Both	Unclear	Yes
				venlafaxine	No	230	40.7 (12.3)	0.62	150-150	Fixed	150	MADRS	32.30							
Weisler 1994	1994	2	2	bupropion	Yes	63	40.2 (*)	*	225-450	Flexible	345	HAMD 21	25.80	6	DSM-III-R	North America	Multi-center	Secondary /Tertiary care	Outpatients only	Yes	Unclear
				trazodone	No	61	40.8 (*)	*	150-400	Flexible	207	HAMD 21	24.90							
WELL 029	unpublished	2	3	bupropion	Yes	25	37.8 (*)	0.44	300-300	Fixed	300	HAMD 21	26.60	4	*	North America	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Unclear
				placebo	No	24	41.5 (*)	0.50	0-0	Fixed	0	HAMD 21	26.20							
WELL AK140016	unpublished	2	2	bupropion	Yes	69	37.6 (10.6)	*	300-300	Fixed	300	HAMD 17	21.90	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				paroxetine	No	71	37 (10.8)	*	20-20	Fixed	20	HAMD 17	22.30							
WELL AK1A4006	unpublished	3	3	fluoxetine	No	155	38.6 (12)	*	20-60	Flexible	*	HAMD 21	25.30	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Unclear
				bupropion	Yes	158	37.1 (10.7)	*	150-400	Flexible	*	HAMD 21	25.60							
				placebo	No	154	37.2 (11.2)	*	0-0	Flexible	0	HAMD 21	25.20							
Wellbutrin 06	unpublished	2	2	bupropion	Yes	56	42 (*)	0.19	300-600	Flexible	*	HAMD 21	28.50	4	*	North America	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Unclear
				placebo	No	29	40.7 (*)	0.26	0-0	Flexible	0	HAMD 21	29.30							
Wellbutrin 25	unpublished	3	3	bupropion	Yes	45	52.4 (*)	0.49	300-300	Fixed	300	HAMD 21	32.40	4	*	North America	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Unclear
				bupropion	Yes	40	47.5 (*)	0.50	450-450	Fixed	450	HAMD 21	34.80							
				placebo	No	43	51.9 (*)	0.51	0-0	Fixed	0	HAMD 21	33.60							
Wheatley 1998	1998	2	2	mirtazapine	Yes	66	47.2 (15.3)	*	15-60	Flexible	40	HAMD 17	26.00	6	DSM-III	Europe	Multi-center	Other/Unclear	Both	Yes	No
				fluoxetine	No	67	47.5 (14.8)	*	20-40	Flexible	24	HAMD 17	26.10							
Wilcox 1994	1994	2	3	amitriptyline	No	50	40 (*)	*	60-300	Flexible	122	HAMD 17	23.8	6	DSM-III	North America	Single center	Secondary /Tertiary care	Outpatients only	Yes	Yes

				placebo	No	49	40 (*)	*	0-0	Flexible	0	HAMD 17	23.5							
Winokur 2003	2003	2	2	mirtazapine	Yes	8	40.9 (*)	*	15-45	Flexible	*	HAMD 21	25.60	8	DSM-IV	North America	Unclear	Other/Unclear	Other/Unclear	No	No
				fluoxetine	No	12	43.5 (*)	*	20-40	Flexible	*	HAMD 21	26.70							
Yang 2003	2003	2	2	milnacipran	Yes	27	43.5 (10.4)	*	50-100	Flexible	*	HAMD 17	25.20	6	DSM-IV	Asia	Multi-center	Secondary/Tertiary care	Outpatients only	Unclear	Unclear
				sertraline	No	26	42 (8.9)	*	50-100	Flexible	*	HAMD 17	23.20							
Yevtushenko 2007	2007	2	3	escitalopram	Yes	109	35.2 (6.5)	0.61	10-10	Fixed	10	MADRS	25.67	6	DSM-IV	Europe	Multi-center	Secondary/Tertiary care	Outpatients only	Unclear	Yes
				citalopram	No	110	35.1 (6.5)	0.56	20-20	Fixed	20	MADRS	35.70							
Young 1987	1987	2	2	fluoxetine	Unclear	32	46.1 (*)	0.68	40-80	Flexible	73	HAMD unspecified	44.00	6	RDC	Europe	Unclear	Secondary/Tertiary care	Outpatients only	Unclear	Yes
				amitriptyline	Unclear	32	46.6 (*)	0.68	50-150	Flexible	122	HAMD unspecified	48.10							
Zajecka 2010 (CAGO178A2301, NCT00411099)	2010	3	3	agomelatine	Yes	170	44.2 (12.3)	0.69	25-25	Fixed	25	HAMD 17	26.70	8	DSM-IV	North America	Multi-center	Primary care	Outpatients only	No	No
				agomelatine	Yes	168	44.2 (12.3)	0.63	50-50	Fixed	50	HAMD 17	27.10							
				placebo	No	173	43.1 (12)	0.68	0-0	Fixed	0	HAMD 17	27.10							
Zhang 2014	2013	2	2	trazodone	No	192	39.5 (12.7)	0.62	150-450	Flexible	273	HAMD 17	21.60	6	DSM-IV	Asia	Multi-center	Secondary/Tertiary care	Both	Yes	Unclear
				placebo	No	190	38.3 (12.2)	0.61	0-0	Flexible	0	HAMD 17	21.90							
Zivkov 1995 (Organon 85146, FDA85146)	1997	2	2	mirtazapine	Yes	103	48.5 (10.6)	*	*	Other/Unclear	*	HAMD 17	27.30	6	DSM-III	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Unclear
				amitriptyline	No	104	47.7 (12.4)	*	*	Other/Unclear	*	HAMD 17	26.20							
845	unpublished	2	3	bupropion	Yes	56	36.4 (*)	0.67	150-450	Flexible	*	HAMD 21	24.60	6	*	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	52	37.4 (*)	0.70	0-0	Flexible	0	HAMD 21	26.80							
003-008 (FDA)	unpublished	3	5	mirtazapine	Yes	30	38 (*)	0.63	15-15	Fixed	15	HAMD 21	26.00	6	DSM-III	North America	Single center	Other/Unclear	Outpatients only	Yes	Unclear
				mirtazapine	Yes	30	40 (*)	0.71	30-30	Fixed	30	HAMD 21	25.50							
				placebo	No	30	39 (*)	0.61	0-0	Fixed	0	HAMD 21	25.80							
003-042	unpublished	4	4	mirtazapine	Yes	70	41 (10.8)	0.71	15-15	Fixed	15	HAMD 21	25.30	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				mirtazapine	Yes	70	39.8 (10.2)	0.56	30-30	Fixed	30	HAMD 21	24.70							
				mirtazapine	Yes	70	42.2 (12.9)	0.60	45-45	Fixed	45	HAMD 21	25.00							
				placebo	No	70	40.8 (10.8)	0.66	0-0	Fixed	0	HAMD 21	25.90							

003-048	unpublished	3	3	mirtazapine	Yes	210	41.4 (12.1)	0.60	45-45	Fixed	45	HAMD 17	22.30	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				fluoxetine	No	210	40.8 (11.6)	0.58	60-60	Fixed	60	HAMD 17	22.80								
				placebo	No	72	40.2 (11.5)	0.61	0-0	Fixed	0	HAMD 17	23.00								
030A2-0004/030A2-0005 (FDA)	unpublished	2	3	nefazodone	Yes	76	44.9 (*)	0.53	50-250	Flexible	175	*	*	6	DSM-III	North America	Multi-center	Other/Unclear	Other/Unclear	Unclear	Yes
				placebo	No	74	41.8 (*)	0.51	0-0	Flexible	0	*	*								
03A0A-004A (FDA)	unpublished	3	3	nefazodone	Yes	80	40.1 (*)	0.54	150-300	Flexible	276	HAMD 17	23.20	6	DSM-III	North America	Multi-center	Other/Unclear	Outpatients only	Unclear	Yes
				nefazodone	Yes	80	39.6 (*)	0.63	300-600	Flexible	514	HAMD 17	23.60								
				placebo	No	80	36.8 (*)	0.64	0-0	Flexible	0	HAMD 17	23.50								
0600A1-300	unpublished	3	*	venlafaxine	Yes	58	*	*	*	Other/Unclear	*	*	*	*	*	*	Unclear	Other/Unclear	Other/Unclear	Unclear	Unclear
				amitriptyline	No	52	*	*	*	Other/Unclear	*	*	*								
				placebo	No	*	*	*	0-0	Other/Unclear	0	*	*								
0600A1-372	unpublished	2	2	venlafaxine	Yes	156	*	*	*	Other/Unclear	*	*	*	6	DSM-IV	North America	Unclear	Other/Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	No	152	*	*	*	Other/Unclear	*	*	*								
0600A-326	unpublished	2	2	venlafaxine	Unclear	60	*	*	*	Other/Unclear	*	*	*	6	DSM-III-R	*	*	Other/Unclear	Other/Unclear	Unclear	Unclear
				clomipramine	Unclear	61	*	*	*	Other/Unclear	*	*	*								
0600A-332	unpublished	2	2	venlafaxine	Yes	27	*	*	*	Other/Unclear	*	*	*	6	DSM-III-R	North America	Unclear	Other/Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	No	24	*	*	*	Other/Unclear	*	*	*								
0600A-347	unpublished	2	2	venlafaxine	Yes	63	*	*	*	Other/Unclear	*	*	*	*	*	*	Unclear	Other/Unclear	Other/Unclear	Unclear	Unclear
				fluvoxamine	No	29	*	*	*	Other/Unclear	*	*	*								
0600A-349	unpublished	2	2	paroxetine	No	85	*	*	*	Other/Unclear	*	*	*	8	DSM-III-R	*	Unclear	Other/Unclear	Other/Unclear	Unclear	Unclear
				venlafaxine	Yes	82	*	*	*	Other/Unclear	*	*	*								
0600A-626	unpublished	2	2	venlafaxine	Yes	79	*	*	*	Other/Unclear	*	*	*	8	DSM-IV	North America	Unclear	Other/Unclear	Outpatients only	Unclear	Unclear
				fluoxetine	No	77	*	*	*	Other/Unclear	*	*	*								
0600A-654	unpublished	2	2	venlafaxine	Yes	131	*	*	*-150	Flexible	*	MADRS	*	12	DSM-IV	*	Unclear	Other/Unclear	Other/Unclear	Unclear	Unclear
				fluoxetine	No	135	*	*	*-40	Flexible	*	MADRS	*								
0600B1-367	unpublished	2	2	paroxetine	No	81	*	*	*	Other/Unclear	*	HAMD unspecified	*	8	DSM-III-R	*	Unclear	Other/Unclear	Other/Unclear	Unclear	Unclear
				venlafaxine	Yes	165	*	*	*	Other/Unclear	*	HAMD unspecified	*								

0600B1-384	unpublished	2	2	venlafaxine	Yes	176	*	*	*	Other/Unclear	*	MADRS	*	6	DSM-III-R	*	Unclear	Other/Unclear	Other/Unclear	Unclear	Unclear
				placebo	No	183	*	*	0-0	Other/Unclear	0	MADRS	*								
0600B1-402	unpublished	2	2	venlafaxine	Yes	295	*	*	*	Other/Unclear	*	*	*	8	DSM-IV	North America	Unclear	Other/Unclear	Outpatients only	Unclear	Unclear
				sertraline	No	293	*	*	*	Other/Unclear	*	*	*								
244 (EMD 68 843-009)	unpublished	2	3	fluoxetine	Unclear	89	*	*	20-20	Flexible	20	HAMD unspecified	24.40	8	DSM-IV	North America	Multi-center	Other/Unclear	Other/Unclear	Yes	Unclear
				placebo	No	95	*	*	0-0	Flexible	0	HAMD unspecified	24.00								
245 (EMD 68 843-010)	unpublished	3	5	vilazodone	Yes	104	*	*	10-20	Flexible	*	HAMD 17	23.80	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				fluoxetine	No	92	*	*	20-20	Fixed	20	HAMD 17	23.50								
				placebo	No	99	*	*	0-0	Fixed	0	HAMD 17	23.40								
246 (SB 659746-003)	unpublished	4	4	vilazodone	Yes	120	*	*	10-10	Fixed	10	HAMD 17	23.80	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				vilazodone	Yes	123	*	*	20-20	Fixed	20	HAMD 17	23.70								
				citalopram	No	117	*	*	20-20	Fixed	20	HAMD 17	23.10								
				placebo	No	129	*	*	0-0	Fixed	0	HAMD 17	23.30								
247 (SB 659746-014)	unpublished	2	2	vilazodone	Yes	109	*	*	5-20	Flexible	*	HAMD 17	23.30	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				placebo	No	111	*	*	0-0	Flexible	0	HAMD 17	23.50								
248 (SB 659746-002)	unpublished	3	4	vilazodone	Yes	133	*	*	10-10	Fixed	10	HAMD 17	24.50	8	DSM-IV	North America	Multi-center	Other/Unclear	Outpatients only	Yes	Unclear
				vilazodone	Yes	132	*	*	20-20	Fixed	20	HAMD 17	24.30								
				placebo	No	128	*	*	0-0	Fixed	0	HAMD 17	23.70								
29060 07 001	unpublished	3	3	paroxetine	Yes	13	40 (*)	0.69	10-60	Flexible	*	HAMD 21	30.50	6	DSM-III	North America	Multi-center	Secondary /Tertiary care	Inpatients only	Yes	Unclear
				placebo	No	12	45.1 (*)	0.42	0-0	Flexible	0	HAMD 21	28.30								
				amitriptyline	No	13	44.6 (*)	0.62	*	Flexible	*	HAMD 21	30.40								
29060/299	unpublished	2	2	paroxetine	Yes	109	40.6 (12.6)	*	20-50	Flexible	*	HAMD 17	27.52	8	ICD-10	Europe	Multi-center	Secondary /Tertiary care	Inpatients only	Unclear	Unclear
				amitriptyline	No	108	40.27 (12.7)	*	100-250	Flexible	*	HAMD 17	28.16								
29060/356	unpublished	2	2	paroxetine	Yes	68	42.2 (1.5)	*	20-20	Fixed	20	HAMD 17	24.60	8	DSM-III-R	Australia	Multi-center	Other/Unclear	Both	Unclear	Unclear
				fluoxetine	No	70	40.6 (1.5)	*	20-20	Fixed	20	HAMD 17	23.80								